REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

RNVA: Rennova Health Analysis and Research Report

2018-08-18 - Asif

Business overview Rennova Health, Inc. (together with its subsidiaries, “Rennova”, “we” or the “Company”) is a provider of an expanding group of health care services for healthcare providers, patients and individuals. Beginning in 2018, the Company intends to focus on and operate two synergistic divisions: 1) Clinical diagnostics through its clinical laboratories; and 2) Hospital operations through its Big South Fork Medical Center, which opened on August 8, 2017, and a hospital in Jamestown Tennessee, including a doctor’s practice, the assets of which the company expect to acquire in the second quarter of 2018, pursuant to the terms of a definitive asset purchase agreement that the company entered into on January 31, 2018, as more fully discussed below. The company believe that its approach will produce a more sustainable business model and the capture of multiple revenue streams from medical providers, patients and hospital services. Management determined that because Big So...

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CLVS: Clovis Oncology Analysis and Research Report

2018-08-13 - Asif

Overview Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The company target its development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. The company's marketed product Rubraca® (rucaparib) is approved on an accelerated basis in the United States by the Food and Drug Administration (“FDA”) as monotherapy for the treatment of patients with deleterious BRCA (human genes associated with the repair of damaged DNA) mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. Continued approval for th...

NYMX: Nymox Pharmaceutical Corp Analysis and Research Report

2018-08-10 - Asif

History of the Corporation Nymox Pharmaceutical Corporation was incorporated under the Canada Business Corporations Act in May 1995 to acquire all of the common shares of DMS Pharmaceutical Inc., a private Corporation which had been carrying on research and development since 1989 on diagnostics and drugs for brain disorders and diseases of the aged with an emphasis on Alzheimer’s disease. In 2015, the Corporation changed domicile to The Bahamas. Nymox Pharmaceutical has funded its operations and projects primarily by selling shares of Nymox’s common stock. On December 1, 1996, its common shares began trading on the Nasdaq Stock Market. Nymox’s common shares also traded on the Montreal Exchange from December 18, 1995 to November 19, 1999. In total through December 31, 2017, Nymox has raised over $108 million through the issuance of common stock or securities exercisable for shares of common stock since its incorporation in May 1995. Organizational Structure Nymox h...

SKLN: Skyline Medical Analysis and Research Report

2018-08-06 - Asif

Overview Skyline is a healthcare products and services company that is expanding its business to take advantage of emerging areas of the dynamic healthcare market through sales of its products, through its partnership with Helomics Holding Corporation (“Helomics”) and through pursuit of other strategic relationships to build value. The company's business highlights include: The company produce and sell the STREAMWAY®System, which the company consider to be the best solution to solve the issue of medical waste disposal, with a cost-effective and environmentally friendly technology which provides infection control associated with toxic waste management. Skyline has historically focused on growing the market for this product in the U.S. and are developing international markets. Skyline has acquired 25% of the capital stock of Helomics, a pioneering Contract Research Organization (“CRO”) Services company that bridges two significant areas of the healthcare industry:...

CGC: Canopy Growth Corporation (TSXV:WEED ) Analysis and Research Report

2018-08-06 - Asif

CORPORATE STRUCTURE Canopy Growth, formerly Tweed Marijuana Inc., is Canada’s first publicly traded medical marijuana company and the first geographically diversified medical marijuana producer with its licences under the ACMPR. Canopy Growth operates eleven production facilities in Canada and currently distributes marijuana across the country to Canadian patients managing a host of medical conditions. Canopy Growth was incorporated pursuant to the provisions of the Canada Business Corporations Act on August 5, 2009 under the name “LW Capital Pool Inc.” The company changed its name to Tweed Marijuana Inc. on March 26, 2014 and later to Canopy Growth Corporation on September 17, 2015. Prior to completing its qualifying transaction on April 3, 2014, Canopy Growth was a “capital pool company” under Policy 2.4 of the TSX Venture Exchange Corporate Finance Manual. As a capital pool company, Canopy Growth had no assets other than cash and did not carry on any operations. On Septem...

INPX: Inpixon Analysis and Research Report

2018-08-04 - Asif

Business Overview The company provide a number of different technology products and services to private and public sector customers. Effective January 1, 2017 the Company has changed the way it analyzes and assesses divisional performance of the Company. The Company has therefore re-aligned its operating segments along those division business lines and now operates in two segments, namely Indoor Positioning Analytics and Infrastructure. The company's premier proprietary product secures, digitizes and optimizes the interior of any premises with indoor positioning and data analytics that provide rich positional information, similar to a global positioning system, and browser-like intelligence for the indoors. Other products and services that the company provide include enterprise computing and storage, virtualization, business continuity, data migration, custom application development, networking and information technology, and business consulting services. Indoor Positio...

AEZS: AEterna Zentaris Analysis and Research Report

2018-07-30 - Asif

History and development of the Company AEterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing pharmaceutical therapies, currently focused on the development and commercialization of Macrilen™ (macimorelin), including through out-licensing arrangements and pursuing in-licensing opportunities. AEterna Zentaris was incorporated on September 12, 1990 under the Canada Business Corporations Act (the "CBCA") and continue to be governed by the CBCA. The company's registered address is located at 1155 René-Lévesque Blvd, West 41st Floor, Montréal, Quebec, Canada H3B 3V2 c/o Stikeman Elliott, LLP. The company's executive offices are located at 315 Sigma Drive, Summerville, South Carolina 29486; its telephone number is (843) 900-3223 and its website is www.aezsinc.com. None of the documents or information found on its website shall be deemed to be included in or incorporated by reference into this Annual Report on Form 20-F, unless such docu...

BCRX: BioCryst Pharmaceuticals Analysis and Research Report

2018-07-30 - Asif

Overview BioCryst Pharmaceuticals is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company focus on oral treatments for rare diseases in which significant unmet medical needs exist and that align with its capabilities and expertise. The company integrate the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. Recent Corporate Highlights RAPIVAB®/ALPIVABTM/RAPIACTA®/PERAMIFLU® (peramivir injection) Peramivir (i.e., product sold or marketed under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU trade names) is approved for commercial sale in the United States, Canada, Japan, Taiwan, Korea, Australia and the European Union. Peramivir is indicated for the treatment of acute uncomplicated influenza in patients wh...

WLL: Keryx Biopharmaceuticals Analysis and Research Report

2018-07-30 - Asif

OVERVIEW Keryx Biopharmaceuticals is a commercial stage biopharmaceutical company focused on bringing innovative medicines to people with kidney disease. The company's long-term vision is to build a multi-product kidney care company. The company's marketed product, Auryxia (ferric citrate) tablets, is an orally available, absorbable, iron-based medicine. Auryxia is approved by the U.S. Food and Drug Administration, or FDA, for two indications. Auryxia was originally approved in September 2014 for the control of serum phosphorus levels in patients with chronic kidney disease, or CKD, on dialysis. Additionally, in November 2017, the FDA approved Auryxia for the treatment of iron deficiency anemia in adults with CKD, not on dialysis. With two FDA-approved indications, the company will leverage its U.S. clinical and commercial infrastructure to make Auryxia available to millions of people with CKD and either iron deficiency anemia or elevated levels of serum phosphorus, which is re...

WLL: Whiting Petroleum Corp. Analysis and Research Report

2018-07-30 - Asif

Overview Whiting Petroleum is an independent oil and gas company engaged in development, production, acquisition and exploration activities primarily in the Rocky Mountains region of the United States. The company's current operations and capital programs are focused on organic drilling opportunities and on the development of previously acquired properties, specifically on projects that the company believe provide the greatest potential for repeatable success and production growth, while selectively pursuing acquisitions that complement its existing core properties. During 2017, the company focused its drilling activity on projects that provide the highest rate of return, while closely aligning its capital spending with cash flows generated from operations. During 2018, the company continue to focus on high-return projects in its asset portfolio that will add production and reserves while generating free cash flows from operations. In addition, the company continually evalu...

ARNA: Arena Pharmaceuticals Analysis and Research Report

2018-07-28 - Asif

Overview Arena Pharmaceuticals is a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver clinical utility across therapeutic areas. The company's proprietary, internally-developed pipeline includes multiple potentially first- or best-in-class programs. The company's three most advanced investigational clinical programs are: ralinepag (APD811), which Arena Pharmaceuticals is currently preparing for a Phase 3 program for pulmonary arterial hypertension, or PAH; etrasimod (APD334), which is being studied in Phase 2 trials for immune and inflammatory conditions with an initial focus on ulcerative colitis and hepatic conditions; and APD371 for visceral pain conditions and which is being studied in a Phase 2 trial for treatment of pain associated with Crohn's disease, or CD. In addition, Arena Pharmaceuticals has collaborations with the following pharmaceutical companies: Everest Medicines Limited (...

APRI: Apricus Biosciences Analysis and Research Report

2018-07-24 - Asif

Overview Apricus Biosciences is a biopharmaceutical company focused on the development of innovative product candidates in the areas of urology and rheumatology. Apricus Biosciences has two product candidates: Vitaros, a product candidate in the United States for the treatment of erectile dysfunction (“ED”), which the company in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan; and RayVa, a product candidate which has completed a Phase 2a clinical trial for the treatment of Raynaud’s Phenomenon, secondary to scleroderma, for which the company own worldwide rights. On February 15, 2018, the FDA issued a complete response letter (a “CRL” and, such CRL, the “2018 CRL”) for the new drug application (“NDA”) for Vitaros. A CRL is a communication from the FDA that informs companies that an application cannot be approved in its present form. In April 2018, the company met with the FDA and confirmed that two new Phase 3 clinical efficacy trials would be nec...

CLF: Cleveland Cliffs Analysis and Research Report

2018-07-24 - Asif

Overview Founded in 1847, Cleveland-Cliffs Inc. is the largest and oldest independent iron ore mining company in the United States. Cleveland Cliffs is a major supplier of iron ore pellets to the North American steel industry from its mines and pellet plants located in Michigan and Minnesota. Additionally, the company operate an iron ore mining complex in Western Australia. By 2020, the company expect to be the sole producer of HBI in the Great Lakes region with the development of its first production plant in Toledo, Ohio. Driven by the core values of safety, social, environmental and capital stewardship, its employees endeavor to provide all stakeholders with operating and financial transparency. The key driver of its business is demand for steelmaking raw materials from U.S. steelmakers. During the first two months of 2018, the U.S. produced approximately 13 million metric tons of crude steel, or about 5% of total global crude steel production, which is in line with the s...

ADAP: Adaptimmune Therapeutics Analysis and Research Report

2018-07-23 - Asif

Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...

TRVN: Trevena Analysis and Research Report

2018-07-02 - Asif

Overview Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Using its proprietary product platform, Trevena has identified and are developing the following product candidates: OLINVOTM (oliceridine) Injection: Trevena is developing OLINVO, a G protein biased ligand of the μ opioid receptor, for the management of moderate-to-severe acute pain where intravenous, or IV, administration is preferred. In February 2017, the company announced positive top-line results from its Phase 3 APOLLO-1 and APOLLO-2 pivotal efficacy studies of OLINVO in moderate-to-severe acute pain following bunionectomy and abdominoplasty, respectively. In both studies, all dose regimens achieved their primary endpoint of statistically greater analgesic efficacy than placebo, as measured by responder rate. In July 2017, the company announced that the company...

PGNX: Progenics Pharmaceuticals Analysis and Research Report

2018-07-02 - Asif

Business Overview The company develop innovative medicines and other technologies to target and treat cancer. The company's pipeline includes: (1) therapeutic agents designed to precisely target cancer (AZEDRA, 1095, and PSMA TTC); (2) prostate-specific membrane antigen (“PSMA”) targeted imaging agents for prostate cancer (1404 and PyLTM); and (3) imaging analysis technology. The company's first commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Salix Pharmaceuticals, Inc. (a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. (“Valeant”)). On October 31, 2017, the company completed the rolling submission of its NDA for AZEDRA. The FDA has accepted its NDA for review, granted its request for Priority Review, and set an initial action date of April 30, 2018 under the PDUFA, which was extended in March by three months to July 30, 2018. Progenics Pharmaceuticals is developing AZEDRA as a treatment for pa...

XGTI: XG Technology Analysis and Research Report

2018-06-27 - Asif

Overview The overarching strategy of xG Technology, Inc. is to design, develop and deliver advanced wireless communications solutions that provide customers in its target markets with enhanced levels of reliability, mobility, performance and efficiency in their business operations and missions. xG’s business lines include the brands of Integrated Microwave Technologies LLC (“IMT”), Vislink Communication Systems (“Vislink” or “VCS”), and xMax. There is considerable brand interaction, owing to complementary market focus, compatible product and technology development roadmaps, and solution integration opportunities. In addition to these brands, xG has a dedicated Federal Sector Group focused on providing next-generation spectrum sharing solutions to national defense, scientific research and other federal organizations. IMT On January 29, 2016, xG completed the acquisition of the net assets that constituted the business of IMT, pursuant to an asset purchase agreement by a...

MRTX: Mirati Therapeutics Analysis and Research Report

2018-06-26 - Asif

Overview Mirati Therapeutics, Inc. is a clinical-stage oncology company developing product candidates to address the genetic, epigenetic and immunological promoters of cancer. The company's precision oncology clinical programs utilize next-generation genomic testing to identify and select cancer patients who are most likely to benefit from targeted drug treatment. In immuno-oncology, Mirati Therapeutics is advancing clinical programs where the ability of its product candidates to improve the immune environment of tumor cells may enhance and expand the efficacy of existing cancer immunotherapy medicines when given in combination. The company's preclinical programs include potentially first-in-class and best-in-class product candidates specifically designed to address mutations and tumors where few treatment options exist. The company approach each of its discovery and development programs with a singular focus: to translate its deep understanding of the molecular drivers of canc...

ARDX: Ardelyx Analysis and Research Report

2018-06-25 - Asif

Company overview Ardelyx is a specialized biopharmaceutical company focused on developing first-in-class, disruptive medicines for the treatment of renal diseases. The company's primary therapeutic focus is on treating people with renal diseases, which affect both the heart and the kidneys. This includes patients with end-stage renal disease, or ESRD, who suffer from elevated serum phosphorus, or hyperphosphatemia; patients with chronic kidney disease, or CKD, and/or heart failure patients with elevated serum potassium, or hyperkalemia. Ardelyx has also developed a number of programs directed toward treating gastrointestinal, or GI, disorders, including the treatment of irritable bowel syndrome with constipation, or IBS-C. The company's portfolio is led by the development of tenapanor, a first-in-class inhibitor of NHE3. In its renal pipeline, tenapanor is being evaluated in a second Phase 3 trial for the treatment of hyperphosphatemia in patients with ESRD who are on dialys...

HLTH: Nobilis Health Corp (TSX:NHC) Analysis and Research Report

2018-06-25 - Asif

Overview The company's operations consist of two reportable business segments, the Medical Segment and the Marketing Segment, each of which is described in more detail in the following paragraphs. The company's Medical Segment owns and manages specialty surgical hospitals, ambulatory surgery centers (ASCs) and multi-specialty clinics. It focuses on improving patient outcomes by providing minimally invasive procedures that can be performed in low-cost, outpatient settings. To promote further improvements in patient satisfaction and clinical outcomes, Nobilis has spent the last two years developing a full suite of ancillary services that the company offer patients treated in its facilities. To date, Nobilis is able to provide a variety of in-house ancillary services, such as Anesthesia, Surgical Assist, Intraoperative Neuromonitoring ("IOM"), and clinical lab testing (collectively, "Nobilis Ancillary Service Lines"). The company's business also utilizes innovative direct-to-co...

CORT: Corcept Therapeutics Analysis and Research Report

2018-06-25 - Asif

Overview Corcept Therapeutics is engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Elevated levels and abnormal release patterns of cortisol are implicated in a broad range of diseases. The company's first approved product, Korlym®, treats patients with Cushing’s syndrome, a rare disease that is caused by excess cortisol activity. The active ingredient in Korlym is mifepristone, a compound that modulates cortisol activity by acting as a competitive antagonist at the glucocorticoid receptor (“GR”), one of the body’s two cortisol receptors. The company first made Korlym available to patients commercially in April 2012. Corcept Therapeutics has discovered three structurally distinct series of proprietary, selective cortisol modulators, all of which share mifepristone’s affinity for GR but, unlike mifepristone, do not bind to the progesterone re...

HIMX: Himax Technologies Analysis and Research Report

2018-06-24 - Asif

History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

VBLT: Vascular Biogenics Analysis and Research Report

2018-06-04 - Asif

Overview Vascular Biogenics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The company conduct business under the name VBL Therapeutics. Vascular Biogenics was incorporated in Israel on January 27, 2000 as a company limited by shares under the name Medicard Ltd. In January 2003, the company changed its name to Vascular Biogenics Ltd. The company's program is based on its proprietary Vascular Targeting System, or VTS, platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels, and which the company believe will allow it to develop product candidates for multiple oncology indications. The company's lead product candidate, VB-111 (ofranergene obadenovec), is a gene-based biologic that Vascular Biogenics is developing for solid tumor indications, and which Vascular Biogenics has advanced to programs for recurrent gliobla...

ALDR: Alder BioPharmaceuticals Analysis and Research Report

2018-06-04 - Asif

Overview Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform the treatment paradigm in migraine. All of its product candidates were discovered and developed by Alder scientists using its proprietary antibody technology platform coupled with a deliberate approach to design and select candidates with properties that the company believe optimize the therapeutic potential for patients and commercial competitiveness. Alder BioPharmaceuticals is focusing its resources and development efforts principally on eptinezumab (ALD403), its most advanced solely-owned product candidate, in order to maximize its therapeutic and commercial potential. Eptinezumab is being evaluated in a pivotal trial program for the prevention of migraine, with a Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) planned for the fi...

XON: Intrexon Corp Analysis and Research Report

2018-06-04 - Asif

Overview The company believe Intrexon is a leader in the field of synthetic biology, focusing on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. Synthetic biology involves the tightly controlled expression of natural and engineered genes (DNA segments) in a variety of animal, plant and microorganismal hosts. The company's historical approach primarily involved an exclusive channel collaboration, or ECC, model in which the company served principally as the technology engine for a partner experienced in a given commercial arena. As its experience has deepened, Intrexon has moved toward more joint ventures, or JVs, and the self-development of projects the company view as particularly compelling and within its increasing areas of expertise. Synthetic biology is a rapidly evolving discipline that applies engineering principles to biological systems to enable rational, design-based cont...

ALQA: Alliqua Analysis and Research Report

2018-06-04 - Asif

Overview Alliqua is a regenerative technologies company that commercializes differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Through its sales and distribution network, together with its proprietary products, the company believe the company offer solutions that allow clinicians to utilize the latest advances in regenerative technologies to bring improved patient outcomes to their practices. The company's contract manufacturing business provides custom hydrogels to the OEM market. Completion of the Asset Sale Transaction with Celularity On May 7, 2018, Alliqua BioMedical, Inc. (the “Company”) completed the sale under the Asset Purchase Agreement (the “APA”) of substantially all of the Company’s assets (the “Asset Sale Transaction”) to Celularity, Inc. (“Celularity”), including certain assets comprising its MIST, Biovance and Interfyl product lines pursuant to the terms of the APA, dated January 5, 2018 ...

ICPT: Intercept Pharmaceuticals Analysis and Research Report

2018-06-01 - Asif

Overview Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases with high unmet medical need utilizing its proprietary bile acid chemistry. The company's one marketed product, OCA, and portfolio of clinical product candidates have the potential to treat orphan and more prevalent liver diseases for which, currently, there are limited therapeutic solutions. OCA was approved in the United States in May 2016 for use in patients with PBC, under the brand name Ocaliva® (obeticholic acid). OCA is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid, that selectively binds to and activates the farnesoid X receptor, or FXR. The company believe OCA has broad liver-protective properties and may effectively counter a variety of chronic insults to the liver that cause fibrosis, or scarring, which can eventually lea...

JD: JD.com Analysis and Research Report

2018-05-29 - Asif

History and Development of the Company The company's chairman and chief executive officer, Mr. Richard Qiangdong Liu, launched an online retail website in January 2004. He subsequently formed a company in Beijing and another company in Shanghai and conducted his online retail business through these two companies. In April 2007, the company established a wholly owned PRC subsidiary, Beijing Jingdong Century Trade Co., Ltd., or Jingdong Century, and the company acquired certain intellectual property rights from the two companies Mr. Liu had established earlier, which ceased business operations and were later liquidated and dissolved. In November 2006, the company incorporated Star Wave Investments Holdings Limited under the laws of the British Virgin Islands as its offshore holding company in order to facilitate international financing. The company later changed the name of this entity to 360buy Jingdong Inc. In January 2014, 360buy Jingdong Inc. was redomiciled in the Cayman ...

AVP: Avon Products Analysis and Research Report

2018-05-28 - Asif

Business Avon Products is a global manufacturer and marketer of beauty and related products. The company commenced operations in 1886 and were incorporated in the State of New York on January 27, 1916. The company conduct its business in the highly competitive beauty industry and compete against other consumer packaged goods ("CPG") and direct-selling companies to create, manufacture and market beauty and non-beauty-related products. The company's product categories are Beauty and Fashion & Home. Beauty consists of skincare, fragrance and color (cosmetics). Fashion & Home consists of fashion jewelry, watches, apparel, footwear, accessories, gift and decorative products, housewares, entertainment and leisure products, children’s products and nutritional products. The company's business is conducted primarily in one channel, direct selling. The company's reportable segments are based on geographic operations in four regions: Europe, Middle East & Africa; South Latin America; N...

FH: FORM Holdings Corp Analysis and Research Report

2018-05-28 - Asif

Overview On January 5, 2018, the company changed its name to XpresSpa Group, Inc. (“XpresSpa Group” or the “Company”) from FORM Holdings Corp. The company's common stock, par value $0.01 per share, which had previously been listed under the trading symbol “FH” on the Nasdaq Capital Market, has been listed under the trading symbol “XSPA” since January 8, 2018. Rebranding to XpresSpa Group aligned its corporate strategy to build a pure-play health and wellness services company, which the company commenced following its acquisition of XpresSpa Holdings, LLC (“XpresSpa”) on December 23, 2016. In 2017, the company recruited employees for positions in both corporate and field teams, accelerated unit growth, reinvested in certain locations and extended leases, significantly streamlined operations, and engaged in new exclusive partnerships that offer XpresSpa customers innovative products and services. *The company currently have two operating segments: wellness and intellectual ...

CAPR: Capricor Therapeutics Analysis and Research Report

2018-05-28 - Asif

Overview Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions. Capricor Therapeutics was originally incorporated in Delaware in August 2005 under the name Nile Pharmaceuticals, Inc. and the company changed its name to Nile Therapeutics, Inc., or Nile, in January 2007. On November 20, 2013, pursuant to that certain Agreement and Plan of Merger and Reorganization dated as of July 7, 2013, as amended by that certain First Amendment to Agreement and Plan of Merger and Reorganization dated as of September 27, 2013, or as amended, the Merger Agreement, by and among Nile, Nile’s wholly-owned subsidiary, Bovet Merger Corp., a Delaware corporation, or Merger Sub, and Capricor, Inc., or Capricor, Merger Sub merged with and into Capricor and Capricor became a w...

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

Grow Your Site Traffic with Fintel Share Buttons

2018-05-22 - Wilton

Promote Your Articles on Fintel Over 300,000 smart investors trust Fintel every month to get the latest stock market news and information. If you own or operate a web site, putting a "Share on Fintel" button on your site is a great way to promote your content to our audience. Adding the Button To install the share button, use the following code: Square Button <a href="https://fintel.io/share" onclick="window.location = 'https://fintel.io/share?url=' + encodeURIComponent(window.location); return false"><img src="https://fintel.io/images/fintel-f-logo.png" width="50" /> </a> Round Button <a href="https://fintel.io/share" onclick="window.location = 'https://fintel.io/share?url=' + encodeURIComponent(window.location); return false"><img src="https://fintel...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

TROV: TrovaGene Analysis and Research Report

2018-05-21 - Asif

BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...

SGMO: Sangamo BioSciences Analysis and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics Analysis and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...

ABEO: Abeona Therapeutics Analysis and Research Report

2018-05-14 - Asif

OVERVIEW Abeona Therapeutics Inc. is a Delaware corporation. Abeona Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. The company's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona Therapeutics is also developing ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition Abeona Therapeutics is developing a proprietary vector platform, ...

CEI: Camber Energy Analysis and Research Report

2018-05-14 - Asif

Overview Camber Energy, Inc., a Nevada corporation, is an independent oil and natural gas company based in San Antonio, Texas. Camber Energy is engaged in the acquisition, development and sale of crude oil, natural gas and natural gas liquids from various known productive geological formations, including from the Hunton formation in Lincoln, Logan and Payne Counties, in central Oklahoma; the Cline shale and upper Wolfberry shale in Glasscock County, Texas; and recently in connection with its entry into the Horizontal San Andres play on the Central Basin Platform of the Permian Basin in West Texas announced on January 3, 2017. Incorporated in Nevada in December 2003 under the name Panorama Investments Corp., the Company changed its name to Lucas Energy, Inc. effective June 9, 2006 and effective January 4, 2017, the Company changed its name to Camber Energy, Inc. The company's primary value drivers are its reserves which must be developed to unlock their full potential. The company...

GNMX: Aevi Genomic Medicine Analysis and Research Report

2018-05-14 - Asif

Overview Aevi Genomic is a clinical stage biopharmaceutical company with an emphasis on identifying the genetic drivers of disease and applying this understanding to the pursuit of differentiated novel therapies primarily for pediatric onset, life-altering diseases, including rare and orphan diseases. The company look to find treatments for genetically defined diseases for which there are limited therapeutic options currently available, with a primary focus on pediatric patients. This strategy begins with identifying and genetically validating a therapeutic target and using genomics to guide product development. The strategy also involves identifying and acquiring otherwise abandoned or overlooked drug candidates and matching targets and mechanisms of action to novel genetic discoveries. Aevi Genomic has partnered with the Center for Applied Genomics, or CAG, at The Children’s Hospital of Philadelphia, or CHOP, to implement a genomic medicine driven approach to drug developm...

CARA: Cara Therapeutics Analysis and Research Report

2018-05-09 - Asif

Overview Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors. Cara Therapeutics is developing a novel and proprietary class of product candidates, led by KORSUVA (CR845/difelikefalin), that target the body’s peripheral nervous system and certain immune cells. The U.S. Food and Drug Administration, or FDA, has conditionally accepted KORSUVA as the trade name for CR845/difelikefalin injection, an investigational drug product for the treatment of itch, whose safety and efficacy have not been fully evaluated by any regulatory authority. In Phase 2 trials, KORSUVA (CR845/difelikefalin) has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus, or CKD-aP, and is c...

CUR: Neuralstem Analysis and Research Report

2018-05-07 - Asif

Overview Neuralstem is focused on the research and development of nervous system therapies based on its proprietary human neural stem cells and its small molecule compounds with the ultimate goal of gaining approval from the United States Food and Drug Administration or FDA, and its international counterparts, to market and commercialize such therapies. Neuralstem is headquartered in Germantown, Maryland. The company's patented technology platform has three core components: Over 300 lines of human, regionally specific neural stem cells, some of which have the potential to be used to treat serious or life-threatening diseases through direct transplantation into the central nervous system; Proprietary screening capability – its ability to generate human neural stem cell lines provides a platform for chemical screening and discovery of novel compounds against nervous system disorders; and Small molecules that resulted from Neuralstem’s neurogenesis screening p...

GLYC: GlycoMimetics Analysis and Research Report

2018-05-07 - Asif

Overview GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. The company's proprietary glycomimetics platform is based on its expertise in carbohydrate chemistry and its understanding of the role carbohydrates play in key biological processes. Using this expertise and understanding, GlycoMimetics is developing a pipeline of proprietary glycomimetics designed to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. The company believe this represents an innovative approach to drug discovery to treat a wide range of diseases. Most human proteins are modified by the addition of complex carbohydrates to the surface of the proteins...

RDUS: Radius Health Analysis and Research Report

2018-05-04 - Asif

Overview Radius Health is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. In April 2017, its first commercial product, TYMLOSTM (abaloparatide) injection, was approved by the U.S. Food and Drug Administration ("FDA") for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In May 2017, the company commenced U.S. commercial sales of TYMLOS and, as of February 2018, TYMLOS was available and covered for approximately 259 million U.S. insured lives, representing approximately 86% of U.S. insured lives. In May 2017, the company also announced positive top-line results from its completed 24-month ACTIVExtend clinical trial for TYMLOS, which met all of ...

AQSZF: Aequus Pharmaceuticals Analysis and Research Report

2018-04-30 - Asif

Overview Aequus is a growing specialty pharmaceutical company, with a foundation built on improving drug delivery of existing medications. Aequus has a diversified portfolio of internally developed clinical and preclinical stage reformulated products as well as a number of commercial stage, third party products that fulfill an identified unmet medical need. The company's development pipeline is focused on advancing products in specialty therapeutic areas with a goal of addressing the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic commercial partnerships for these programs in other markets that would maximize the reach of its product candidates worldwide. The company's most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need for...

ZGNX: Zogenix Analysis and Research Report

2018-04-30 - Asif

Company Overview The company currently own and control worldwide development and commercialization rights to ZX008, its lead Phase 3 product candidate. ZX008 is low-dose fenfluramine for the treatment of seizures associated with two rare and catastrophic forms of childhood-onset epilepsy: Dravet syndrome and Lennox-Gastaut syndrome (“LGS”). Dravet syndrome is a rare form of pediatric-onset epilepsy with life threatening consequences for patients and for which current treatment options are very limited. ZX008 has received orphan drug designation in the United States and the European Union (“the EU”) for the treatment of Dravet syndrome. In addition, ZX008 for the treatment of Dravet syndrome received Fast Track designation from the U.S. Food and Drug Administration (the “FDA”) in January 2016 and Breakthrough Therapy designation in February 2018. The company initiated its Phase 3 clinical trials in North America (Study 1501) in January 2016 and in Europe and Australia in J...

MRNS: Marinus Pharmaceuticals Analysis and Research Report

2018-04-27 - Asif

Overview Marinus Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. The company's clinical stage product candidate, ganaxolone, is a positive allosteric modulator of GABAA being developed in three different dose forms: intravenous (IV), capsule and liquid. The multiple dose forms are intended to maximize the therapeutic range of ganaxolone for adult and pediatric patient populations, in acute and chronic care, and both in-patient and self-administered settings. Ganaxolone exhibits anti-seizure, anti-anxiety and anti-depressive actions via its effects on synaptic and extrasynaptic GABAA receptors. The company's Pipeline Marinus Pharmaceuticals is developing ganaxolone to treat children suffering from rare epilepsies and both adults and children suffering from other neuropsychiatric conditions where there is a mechanistic rationale for ganaxolo...

TOPS: TOP Ships Analysis and Research Report

2018-04-27 - Asif

History and Development of the Company The company's predecessor, Ocean Holdings Inc., was formed as a corporation in January 2000 under the laws of the Republic of the Marshall Islands and renamed Top Tankers Inc. in May 2004. In December 2007, Top Tankers Inc. was renamed TOP Ships Inc. The company's common stock is currently listed on Nasdaq under the symbol "TOPS." The current address of its principal executive office is 1 Vasilisis Sofias and Megalou Alexandrou Str, 15124 Maroussi, Greece. On January 29, 2015 and March 31, 2015, agreements were consummated for the sale and leaseback of the M/T Stenaweco Energy and M/T Stenaweco Evolution, respectively. The sale and leaseback agreements were entered into with a third party and generated gross proceeds of $57 million. The vessels have been chartered back on a bareboat basis for seven years at a bareboat hire of $8,586 per day and $8,625 per day, respectively. In addition, TOP Ships has the option to buy back each vessel f...

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

ANY: Sphere 3D Corp Analysis and Research Report

2018-04-09 - Asif

Overview Sphere 3D provides next-generation solutions for standalone storage and long-term data archive products, as well as technologies that converge the traditional silos of compute, storage and network into one integrated “hyper-converged” or converged solution. The company provide enterprise storage management solutions, the archiving of the data created by these solutions, and the ability to connect to public cloud services such as Microsoft Azure for additional delivery options and hybrid cloud capabilities. The company's solutions are tightly integrated and include a patented portfolio for operating systems for storage, proprietary virtual desktop orchestration software, and proprietary application container software. The company's software, combined with commodity x86 servers, or its purpose built appliances, deliver solutions that provide application mobility, security, data integrity and simplified management. These solutions can be deployed through a public, private...

RCKT: Rocket Pharmaceuticals Analysis and Research Report

2018-04-09 - Asif

Overview Rocket Pharmaceuticals, Ltd. is a multi-platform biotechnology company focused on the development of first-in-class gene therapies for rare and devastating pediatric diseases. Rocket Pharma has two lentiviral virus (“LVV”) programs currently undergoing clinical testing targeting Fanconi Anemia (“FA”), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, and three additional LVV programs targeting other rare genetic diseases. In addition, Rocket Pharma has an adeno-associated virus (“AAV”) program for which it expects to file an investigational new drug (“IND”) application in the next 12 months, which will permit the commencement of human clinical studies thereafter. Rocket Pharma has full global commercialization and development rights to all of its product candidates under royalty-bearing license agreements, with the exception of the CRISPR/Cas9 development program (described below) for which Rock...

ITEK: Inotek Pharmaceuticals Corporation Analysis and Research Report

2018-04-09 - Asif

Overview On January 4, 2018 Inotek Pharmaceuticals Corporation merged with Rocket Pharmaceuticals detail below. Rocket Pharmaceuticals, Ltd. is a multi-platform biotechnology company focused on the development of first-in-class gene therapies for rare and devastating pediatric diseases. Rocket Pharma has two lentiviral virus (“LVV”) programs currently undergoing clinical testing targeting Fanconi Anemia (“FA”), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, and three additional LVV programs targeting other rare genetic diseases. In addition, Rocket Pharma has an adeno-associated virus (“AAV”) program for which it expects to file an investigational new drug (“IND”) application in the next 12 months, which will permit the commencement of human clinical studies thereafter. Rocket Pharma has full global commercialization and development rights to all of its product candidates under royalty-bearing lice...

ZYNE: Zynerba Pharmaceuticals Analysis and Research Report

2018-04-08 - Asif

Company Overview Zynerba Pharmaceuticals is a clinical stage specialty pharmaceutical company dedicated to the development and commercialization of innovative transdermal pharmaceutically-produced cannabinoid treatments for rare (meeting the U.S. Food and Drug Administration’s, or FDA’s, designation of an orphan disease, affecting fewer than 200,000 people in the United States) and near-rare (affecting fewer than one million people in the United States) neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. Zynerba Pharmaceuticals is currently evaluating two patent protected product candidates, ZYN002 and ZYN001, in four neuropsychiatric indications. In 2017, the company completed three Phase 2 clinical trials for ZYN002 and two of those studies have open-label extensions that are ongoing. In 2018 the company plan to initiate additional clinical trials evaluating ZYN002 for the treatment of behavioral symptoms of Fragile X syndr...

PETX: Aratana Therapeutics Analysis and Research Report

2018-04-03 - Asif

Company overview Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for dogs and cats. As a pioneer in pet therapeutics, Aratana’s mission is to deliver safe and effective therapeutics that elevate the standard of care in veterinary medicine. The company work with companion animal veterinarians to bring new therapeutics to market that support the needs of pets and their owners. Aratana Therapeutics was incorporated on December 1, 2010 under the laws of the State of Delaware. Aratana Therapeutics has completed several licensing transactions and acquisitions to build its pipeline. Aratana Therapeutics has three marketed therapeutics, including ENTYCE® (capromorelin oral solution) for appetite stimulation in dogs; NOCITA® (bupivacaine liposome injectable suspension) as a local post-operative analgesia for cranial cruciate ligament surgery in dogs; and GALLIPRANT® (grapiprant tablets) for the cont...

ENDP: Endo International (TSX:ENL) Analysis and Research Report

2018-03-29 - Asif

Overview Endo International plc is an Ireland-domiciled, global specialty pharmaceutical company focused on generic and branded pharmaceuticals. The company aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of generic and branded drugs to meet patients’ needs. Endo International plc was incorporated in Ireland in 2013 as a private limited company and re-registered effective February 18, 2014 as a public limited company. The company's ordinary shares are traded on the NASDAQ Global Market (NASDAQ) under the ticker symbol “ENDP.” References throughout to “ordinary shares” refer to Endo International plc’s ordinary shares, 1,000,000,000 authorized, par value $0.0001 per share. In addition, Endo International has 4,000,000 euro deferred shares outstanding, par value of $0.01 each. The company's global headquarters are located at Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland (telephone number: 011...

GBT: Global Blood Therapeutics Analysis and Research Report

2018-03-26 - Asif

Overview Global Blood Therapeutics is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. The company's lead product candidate is voxelotor (previously known as GBT440), an oral, once-daily therapy that modulates hemoglobin’s affinity for oxygen, which the company believe inhibits hemoglobin polymerization in sickle cell disease, or SCD. Global Blood Therapeutics is currently evaluating voxelotor in SCD in a Phase 3 clinical trial in adult and adolescent patients with SCD. In addition, Global Blood Therapeutics is evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase 2a clinical trial of adolescent and pediatric patients with SCD, and in July 2017 the company announced that Global Blood Therapeutics has expanded this open-label trial to include a new single-dose cohort in children aged 6-11. In December 2015, the Food and Dr...

MZOR: Mazor Robotics (OTC:MZRTF) Analysis and Research Report

2018-03-23 - Asif

Overview Mazor Robotics is a medical device company developing and marketing innovative surgical guidance systems and complementary products. The company's expertise is computerized and imaging-based systems, primarily in the field of spine surgery. The company's Surgical Guidance Systems enable surgeons to advance from freehand surgical procedures to accurate, pre-planned, state-of-the-art, precision guided procedures. The company's Surgical Guidance Systems are used in multiple types of spine surgeries, whether open or minimally invasive, for a variety of clinical indications. The company's Mazor X System, its Renaissance system and its predecessor have been used in over 24,000 spine surgeries, including fusion, correction of spinal deformities, biopsy collection, tumor excision and cement augmentations. The company's Surgical Guidance Systems have the ability to improve clinical outcomes for patients, and may provide a safer surgical environment for surgeons and operating ro...

PUFXF: PUF Ventures (CNSX:PUF) Analysis and Research Report

2018-03-19 - Asif

Business History The Company was incorporated on June 24, 2004 under the laws of the Province of British Columbia under incorporation number BC0698428. On July 20, 2004, the Company changed its name from 0698428 BC Ltd. to High Ridge Resources Inc. On January 1, 2010, the Company changed its name from High Ridge Resources Inc. to New High Ridge Resources Inc. On February 7, 2011, the Company changed its name from New High Ridge Resources Inc. to Newton Gold Corp. On November 7, 2013, the Company changed its name from Newton Gold Corp. to Chlormet Technologies, Inc. On ovember 13, 2015, the Company changed its name from Chlormet Technologies, Inc. to PUF Ventures Inc. The Company’s head office and registered and records office is located at Suite 804 - 750 West Pender Street, Vancouver, British Columbia, V6C 2T7. On March 1, 2006, the Company was listed and commenced trading on the TSX Venture Exchange under the symbol “CMT” until June 18, 2014. Effective June 19, 2014, the C...

MQPXF: Matica Enterprises (CNSX:MMJ) Analysis and Research Report

2018-03-19 - Asif

Overview The Company was incorporated pursuant to the Business Corporation Act (British Columbia) in November 2007 under the name of Cadman Resources Inc. The Company was initially listed in July 2008 as a capital pool company ("CPC"), as defined in the policies of the TSX Venture Exchange (the “Exchange”). In December 2010, the listing of the Company’s shares was transferred to the NEX Board. In July 2012, the Company began trading on the Canadian National Stock Exchange (“CNSX”) under the symbol “CUZ” and voluntarily delisted from the NEX board. In April 2014, the Company changed its name to Matica Graphite Inc. and began trading under the new symbol “GRF”. In July 2014, the Company changed its name to Matica Enterprises Inc. In July 2014, the Company’s shares were accepted for trading on the Frankfurt Stock Exchange. In 2014, the Company completed a change of business with a primary focus in the medical marijuana industry. As a result of the change in business focus, t...

PANXF: Platinex (TSXV:PTX) Analysis and Research Report

2018-03-16 - Asif

Overview The Company was incorporated on August 12, 1998 under the laws of the Province of Ontario and trades on the Canadian Securities Exchange under the symbol “PTX”. The Company is at the exploration and evaluation stage and is engaged in the acquisition, exploration and development of properties for the mining of precious and base metals. The Company is in the process of exploring its resource properties for mineral resources and has not determined whether the properties contain economically recoverable reserves. Recovery of amounts reported for mineral properties and related deferred expenditures is dependent upon the existence of economically recoverable reserves, confirmation of the Company’s interest in the underlying mineral claims, the ability of the Company to obtain necessary financing to conduct exploration and the ability of the Company to recover value for its properties and/or upon future profitable production. The business of mining and exploring for minera...

HTZ: Hertz Global Holdings Analysis and Research Report

2018-03-12 - Asif

BUSINESS Hertz Holdings was incorporated in Delaware in 2015 to serve as the top-level holding company for Rental Car Intermediate Holdings, LLC, which wholly owns Hertz, Hertz Global's primary operating company. Hertz was incorporated in Delaware in 1967 and is a successor to corporations that have been engaged in the vehicle rental and leasing business since 1918. The company operate its vehicle rental business globally through the Hertz, Dollar and Thrifty brands from approximately 10,200 corporate and franchisee locations in North America, Europe, Latin America, Africa, Asia, Australia, The Caribbean, the Middle East and New Zealand. Hertz Global Holdings is one of the largest worldwide airport general use vehicle rental companies and its Hertz brand name is one of the most recognized in the world, signifying leadership in quality rental services and products. Hertz Global Holdings has an extensive network of rental locations in the U.S. and in all major European markets...

PBYI: Puma Biotechnology Analysis and Research Report

2018-03-12 - Asif

Company Overview Puma Biotechnology is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-license the global development and commercialization rights to three drug candidates – PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor, or TKI, that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, Puma Biotechnology is primarily focused on the U.S. commercialization of NERLYNX (neratinib), its first U.S. Food and Drug Administration, or FDA, approved product, and on the further development of the oral version of neratinib for additional indications in the treatment of HER2-positive breast cancer. The company believe neratinib has clinical application in the treatment of several other cancers as well, including non-small cell lung cancer and other tumor types tha...

CLDX: Celldex Therapeutics Analysis and Research Report

2018-03-10 - Asif

Overview Celldex Therapeutics, Inc., which is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company's drug candidates, including antibodies, antibody-drug conjugates and other protein-based therapeutics, are derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. The company's latest stage drug candidate, glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate in a randomized, Phase 2b study for the treatment of triple negative breast cancer and a Phase 2 study for the treatment of metastatic melanoma. Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient's immune response against cancer. The company established proof of principle in a P...

MBOT: Microbot Medical Analysis and Research Report

2018-03-08 - Asif

Microbot is a pre-clinical medical device company specializing in the research, design and development of next generation micro-robotics assisted medical technologies targeting the minimally invasive surgery space. Microbot is primarily focused on leveraging its micro-robotic technologies with the goal of improving surgical outcomes for patients. Microbot is currently developing its first two product candidates: The Self Cleaning Shunt, or SCS, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and TipCAT, a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures. Microbot’s product candidates are being designed to bring greater functionality to conventional medical devices and to reduce the known risks associated with such devices. Microbot is currently aiming to complete pre-clinical studies required for regulatory submission for the SCS as well as the TipCAT within the next 21 months. Microbot ha...

SENS: Senseonics Holdings Analysis and Research Report

2018-03-08 - Asif

Senseonics Holdings was originally incorporated as ASN Technologies, Inc. in Nevada on June 26, 2014. On December 4, 2015, the company were reincorporated in Delaware and changed its name to Senseonics Holdings, Inc. Also, on December 4, 2015, the company entered into a merger agreement with Senseonics, Incorporated and SMSI Merger Sub, Inc., or the Merger Agreement, to acquire Senseonics, Incorporated. Senseonics, Incorporated was originally incorporated on October 30, 1996 and commenced operations on January 15, 1997. The transactions contemplated by the Merger Agreement were consummated on December 7, 2015, referred to herein as the Acquisition. Pursuant to the terms of the Merger Agreement, (i) all issued and outstanding shares of Senseonics, Incorporated's preferred stock were converted into shares of Senseonics, Incorporated common stock, $0.01 par value per share, or the Senseonics Shares, (ii) all outstanding Senseonics Shares were exchanged for 57,739,953 shares of its common ...

ONCS: OncoSec Medical Incorporated Analysis and Research Report

2018-03-06 - Asif

OncoSec Medical is a biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer. The company's core platform technology, ImmunoPulse®, is a drug-device therapeutic modality comprised of a proprietary intratumoral electroporation delivery device. The ImmunoPulse® platform is designed to deliver DNA-encoded drugs directly into a solid tumor and promote an inflammatory response against cancer. The ImmunoPulse® device can be adapted to treat different tumor types, and consists of an electrical pulse generator, a reusable handle and disposable applicators. The company's lead product candidate, ImmunoPulse® IL-12, uses its electroporation device to deliver a DNA-encoded interleukin-12, or IL-12, called tavokinogene telseplasmid, or tavo, with the aim of reversing the immunosuppressive microenvironment in the tumor and engendering a systemic ...

List of XBRL Resources

2018-03-05 - Wilton

XBRL is a standard for representing digital financial statements. XBRL formatted financial data is required by the SEC for all public companies that file financial statements, and is the source for all financial data displayed on Fintel. Here are some XBRL resources that we have found useful in our work. http://www.xbrlsite.com/2014/Reference/Mapping.pdf https://xbrl.us/xbrl-taxonomy/2018-us-gaap/ http://xbrl.squarespace.com/intelligent-xbrl/ [http://xbrlsite.azurewebsites.net/2017/IntelligentDigitalFinancialReporting/Part03_Chapter06.2_ValidatingModelStructureAndFundamentalAccountingConceptRelations.pdf](http://xbrlsite.azurewebsites.net/2017/IntelligentDigitalFinancialReporting...

GILD: Gilead Sciences Analysis and Research Report

2018-03-04 - Asif

Overview Gilead Sciences, Inc. (Gilead, we, its or us), incorporated in Delaware on June 22, 1987, is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, the company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead Sciences has operations in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead’s primary areas of focus include HIV/AIDS, liver diseases, hematology/oncology and inflammation/respiratory diseases. The company seek to add to its existing portfolio of products through its internal discovery and clinical development programs and through product acquisition and in-licensing strategies. 2017 Highlights Over the past year, the company continued to bring best-in-class drugs to market that advance the standard of care by off...

FTR: Frontier Communications Analysis and Research Report

2018-03-04 - Asif

Business Frontier Communications Corporation (Frontier) is a provider of communications services in the United States, with approximately 4.9 million customers, 3.9 million broadband subscribers and 22,700 employees, operating in 29 states. In recent years, Frontier has completed multiple acquisitions. On April 1, 2016, the company acquired the wireline operations of Verizon Communications, Inc. in California, Texas and Florida for a purchase price of $10,540 million in cash and assumed debt. The company conduct business with both consumer and commercial customers. Consumer. The company provide broadband, video, voice and other services and products to its consumer customers. The company deliver these services generally over a combination of fiber and copper-based networks. Commercial (small, medium and large enterprise business (SME) as well as wholesale customers). Com...

NBEV: New Age Beverages Corporation Analysis and Research Report

2018-03-01 - Asif

New Age Beverages is a leading organic and natural healthy functional beverage company engaged in the development, marketing, sales and distribution of a portfolio of Ready-to-Drink (RTD) better-for-you beverages. The company has competitive entrants in the top 5 fastest growing segments of the beverage industry and competes in the RTD Tea, RTD Coffee, Coconut Water, Kombucha, Functional Waters, Rehydration Beverages, Carbonated Beverages and Energy drink segments. The company differentiate its brands through functional characteristics and ingredients and offer only organic and natural better-for-you products, with no HFCS, no GMOs, no preservatives, and only natural flavors, fruits, and other ingredients. The company manufacture its products in its own fully-integrated manufacturing facilities and through a network of ten additional manufacturers strategically located throughout the United States. The company's products are currently distributed in 10 countries internationally, and in...

NH: NantHealth Analysis and Research Report

2018-03-01 - Asif

NantHealth is a leading next-generation, evidence-based, personalized healthcare company focused on enabling its clients to fundamentally change the diagnosis, treatment and pharmacoeconomics of cancer and other critical illnesses. The company believe a molecular-driven, systems-based approach to making clinical treatment decisions based on large-scale, real time biometric and phenotypical data will become the standard of care initially for patients with cancer and, ultimately, other critical illnesses. The company derive revenue from selling GPS Cancer (our Genomic Proteomic Spectrometry Cancer test, a unique, comprehensive molecular test and decision support solution that measures the proteins present in the patient's tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor & normal samples), to which the company obtained exclusive access from an affiliate, and from selling software solutions to healthcare payors, self-insured employers and healthcare systems....

TXMD: TherapeuticsMD Analysis and Research Report

2018-02-26 - Asif

TherapeuticsMD was incorporated in Utah in 1907 under the name Croff Mining Company, or Croff. Prior to 2008, Croff’s operations consisted entirely of oil and natural gas leases. Due to a spin-off of its operations in December 2007, Croff had no business operations or revenue source and had reduced its operations to a minimal level although it continued to file reports required under the Securities Exchange Act of 1934, or the Exchange Act. As a result of the spin-off, Croff was a “shell company” under the rules of the Securities and Exchange Commission, or the SEC. In July 2009, Croff (i) closed a transaction to acquire America’s Minority Health Network, Inc. as a wholly owned subsidiary, (ii) ceased being a shell company, and (iii) experienced a change in control in which the former stockholders of America’s Minority Health Network, Inc. acquired control of its company. On June 11, 2010, the company closed a transaction to acquire Spectrum Health Network, Inc. as a wholly owned subsi...

BLCM: Bellicum Pharmaceuticals Analysis and Research Report

2018-02-26 - Asif

Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders. Bellicum Pharmaceuticals is using its proprietary Chemical Induction of Dimerization, or CID technology platform to engineer its product candidates with switch technologies that are designed to control components of the immune system in real time. By incorporating its CID platform, its product candidates may offer better safety and efficacy outcomes than are seen with current cellular immunotherapies. Bellicum Pharmaceuticals is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, chimeric antigen receptor T cell therapy, or CAR T, and T cell receptors, or TCRs. HSCT, also known as bone marrow transplanta...

ADMS: Adamas Pharmaceuticals Analysis and Research Report

2018-02-24 - Asif

Adamas Pharmaceuticals, Inc., seek to redefine the treatment experience for patients suffering from chronic neurological diseases. The company's vision is grand, its goal bold: to create and commercialize a new generation of medicines intended to lessen the burden of disease on patients, caregivers and society. With a new commercial medicine and robust pipeline of investigational programs focused on meaningfully differentiated treatment options for patients, the company believe Adamas Pharmaceuticals is well on its way. The company's therapeutic targets include a broad range of neurologic diseases, including Parkinson’s disease, multiple sclerosis, epilepsy and Alzheimer’s disease. The company's treatment innovations stem from a deep scientific understanding of time-dependent biology – the deliberate mapping of disease patterns and drug activity – along with a goal to meaningfully increase the efficacy of known molecules without compromising tolerability. This approach is designed t...

PLUG: Plug Power Analysis and Research Report

2018-02-22 - Asif

Plug Power Inc., or the Company, is a leading provider of alternative energy technology focused on the design, development, commercialization and manufacture of hydrogen fuel cell systems used primarily for the material handling and stationary power market. Plug Power is focused on proton exchange membrane, or PEM, fuel cell and fuel processing technologies, fuel cell/battery hybrid technologies, and associated hydrogen storage and dispensing infrastructure from which multiple products are available. A fuel cell is an electrochemical device that combines hydrogen and oxygen to produce electricity and heat without combustion. Hydrogen is derived from hydrocarbon fuels such as liquid petroleum gas, or LPG, natural gas, propane, methanol, ethanol, gasoline or biofuels. Plug Power develops complete hydrogen delivery, storage and refueling solutions for customer locations. Hydrogen can also be obtained from the electrolysis of water, or produced on-site at consumer locations through a pr...

FINL: The Finish Line Analysis and Research Report

2018-02-22 - Asif

The Company is a premium retailer of athletic shoes, apparel, and accessories for men, women, and kids, throughout the United States, Guam, and Puerto Rico, through multiple operating segments. Headquartered in Indianapolis, Finish Line runs approximately 950 branded locations in U.S. malls and shops inside Macy’s department stores. Finish Line employs more than 14,000 associates who connect customers to sneaker culture through style and sport Brick and mortar comparable sales are the change in net sales year over year for the reporting periods presented from Finish Line stores open longer than one year, beginning in the thirteenth month of a store’s operation. Expanded stores are excluded from the brick and mortar comparable sales calculation until the thirteenth month following the re-opening of the store and temporarily closed stores are excluded during the months that the store is closed. Brick and mortar comparable sales do not include sales from shops within department stores....

IMGN: Immunogen Analysis and Research Report

2018-02-19 - Asif

ImmunoGen is a biotechnology company that is progressing toward becoming a fully-integrated company delivering innovative antibody-drug conjugate, or ADC, therapies that meaningfully improve the lives of people with cancer. An ADC with its proprietary technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a “payload” to kill the tumor cell once the ADC has bound to its target. ADCs are an expanding approach to the treatment of cancer, with four approved products and the number of agents in development growing significantly in recent years. Immunogen has established a leadership position in ADCs. The company's proprietary portfolio is led by mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha, or FRα. In late 2016, the company initiated a Phase 3 registration trial, FORWARD I, with mirvetuximab soravtansine for use as single-agent therapy to treat patients with platinum-resi...

PLSE: Pulse Biosciences Analysis and Research Report

2018-02-19 - Asif

Pulse Biosciences is a clinical-stage medical technology company developing a non-thermal tissue treatment platform technology based upon its proprietary Nano-Pulse Stimulation (“NPS”) technology and pursuing applications in oncology, dermatology, general tissue treatment and veterinary medicine. NPS is a novel patented technology which leverages nano-second duration energy pulses that have demonstrated effective local tumor control and the initiation of an adaptive immune response in pre-clinical studies. Pulse Biosciences is pursuing a number of clinical applications for NPS, including oncology, dermatology, aesthetics and other minimally invasive applications where the company believe NPS has the potential to compare favorably with current therapies and treatments. Pulse Biosciences is currently conducting research and development activities in pursuit of commercial applications for its NPS technology, but Pulse Biosciences has not yet commercialized or recognized revenue from its t...

FLXN: Flexion Therapeutics Analysis and Research Report

2018-02-19 - Asif

Flexion Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis, referred to as OA. On October 6, 2017, the U.S Food and Drug Administration, or FDA, approved Zilretta, as the first and only extended-release, intra-articular, or IA (meaning in the joint), injection indicated for the management of OA related knee pain. Zilretta is a non-opioid therapy that employs its proprietary microsphere technology to provide pain relief for over 12 weeks. Zilretta is not intended for repeat administration, as the efficacy and safety of repeat administration of Zilretta have not been evaluated. Flexion Therapeutics was incorporated in Delaware in November 2007, and to date Flexion Therapeutics has devoted substantially all of its resources to developing its product candidates, including conducting ...

ACAD: ACADIA Pharmaceuticals Analysis and Research Report

2018-02-15 - Asif

ACADIA Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system, or CNS, disorders. ACADIA Pharmaceuticals has a portfolio of product opportunities led by its novel drug, NUPLAZID (pimavanserin), which was approved by the U.S. Food and Drug Administration, or FDA, on April 29, 2016 for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, or PD Psychosis, and is the only drug approved in the United States for this condition. NUPLAZID is a selective serotonin inverse agonist, or SSIA, preferentially targeting 5-HT2A receptors. Through this novel mechanism, NUPLAZID demonstrated significant efficacy in reducing the hallucinations and delusions associated with PD Psychosis in its Phase III pivotal trial and has the potential to avoid many of the debilitating side effects of existing antipsychotics, none of which are approved by the ...

PULM: Pulmatrix Analysis and Research Report

2018-02-15 - Asif

Business The Company is a clinical stage biotechnology company focused on the discovery and development of a novel class of inhaled therapeutic products. The Company's proprietary dry powder delivery platform, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), is engineered to deliver small, dense particles with highly efficient dispersibility and delivery to the airways, which can be used with an array of dry powder inhaler technologies and can be formulated with a variety of drug substances. The Company is developing a pipeline of iSPERSE-based therapeutic candidates targeted at prevention and treatment of a range of respiratory diseases and infections with significant unmet medical needs. Since its inception in 2003, Pulmatrix has devoted substantially all of its efforts to product research and development. The company do not have any products approved for sale and have not generated any revenue from product sales. Pulmatrix has funded its operations to date th...

EXEL: Exelixis Analysis and Research Report

2018-02-15 - Asif

Exelixis is a biotechnology company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since its founding in 1994, three products discovered at Exelixis have progressed through clinical development, received regulatory approval, and entered the marketplace. Two are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including VEGF, MET, AXL and RET receptors: CABOMETYX® (cabozantinib) tablets approved for previously treated advanced renal cell carcinoma, or RCC, and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer, or MTC. The third product, COTELLIC® (cobimetinib) tablets, is a reversible inhibitor of MEK, marketed under a collaboration with Genentech (a member of the Roche Group), and is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a variety of forms of cancer...

HALO: Halozyme Therapeutics Analysis and Research Report

2018-02-13 - Asif

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. The company's proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for potential clinical benefit. The company exploit its technology and expertise using a two pillar strategy that the company believe enables it to manage risk and cost by: (1) developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing its technology to biopharmaceutical companies to collaboratively develop products that combine its technology with the collaborators’ proprietary compounds. The majority of its approved product and product candidates are based on rHuPH20, its patented recombinant human hyaluronidase enzyme. The company's proprietary development pipeline con...

JCP: J.C. Penney Co. Analysis and Research Report

2018-02-13 - Asif

J. C. Penney Company, Inc. is a holding company whose principal operating subsidiary is J. C. Penney Corporation, Inc. (JCP). JCP was incorporated in Delaware in 1924, and J. C. Penney Company, Inc. was incorporated in Delaware in 2002, when the holding company structure was implemented. The holding company has no independent assets or operations and no direct subsidiaries other than JCP. The holding company is a co-obligor (or guarantor, as appropriate) regarding the payment of principal and interest on JCP’s outstanding debt securities. The guarantee of certain of JCP’s outstanding debt securities by the holding company is full and unconditional. Growth Initiatives The company's growth strategy for 2017 focuses on the following five initiatives: Beauty; Home refresh and toys; Omnichannel; Pricing strategy; and Women's apparel business. First, the company continue to focus on its beauty categories of Sephora and The Salon by InStyle. J.C. Penney has ...

TNDM: Tandem Diabetes Care Analysis and Research Report

2018-02-10 - Asif

Tandem Diabetes Care is a medical device company with an innovative approach to the design, development and commercialization of products for people with insulin-dependent diabetes. The company believe that its competitive advantage is rooted in its unique consumer-focused approach and proprietary technology platform. This allows it to deliver innovative hardware and software solutions to meet the various needs and preferences of people with diabetes and their healthcare providers. The company manufacture and sell insulin pump products in the United States that are designed to address large and differentiated segments of the insulin-dependent diabetes market. The company's insulin pump products include: the t:slim X2 Insulin Delivery System, or t:slim X2, its next-generation flagship product that is updatable and designed to display Dexcom G5 continuous glucose monitoring, or CGM, sensor information directly on the pump Home Screen; and the t:flex Insulin Delivery System, or ...

NEOS: Neos Therapeutics Analysis and Research Report

2018-02-10 - Asif

Neos Therapeutics is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platform, which Neos Therapeutics has already used to develop Adzenys XR-ODT, Cotempla XR-ODT and Adzenys ER, for the treatment of attention deficit hyperactivity disorder (ADHD). The company's products and product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. The company's proprietary modified-release drug delivery platform has enabled it to create novel, extended-release ODT and liquid suspension dosage forms. The company received approval from the U.S. Food and Drug Administration (FDA), for Adzenys XR-ODT, its amphetamine XR-ODT, on January 27, 2016 and launched the commercialization of this product on May 16, 2016. The company received approval from the FDA for Cotempla XR-ODT, its methylphenidate XR-ODT for t...

CVRS: Corindus Vascular Robotics Analysis and Research Report

2018-02-08 - Asif

The company design, manufacture and sell precision vascular robotic-assisted systems for use in interventional vascular procedures (the “CorPath® System”). The CorPath System is the first medical device cleared by the United States Food and Drug Administration (“FDA”) to bring robotic-assisted precision to radial, coronary and peripheral procedures. During these procedures, the interventional cardiologist sits at a radiation-shielded workstation to advance interventional devices with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. The CorPath System brings robotic precision to radial and complex interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. In October 2016, the company announced that the company had received 510(k) clearance from ...

AXSM: Axsome Therapeutics Inc Analysis and Research Report

2018-02-08 - Asif

Business Overview Axsome Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for central nervous system, or CNS, disorders for which there are limited treatment options. By focusing on this therapeutic area, Axsome Therapeutics is addressing significant and growing markets where current treatment options are limited or inadequate. The company's product candidate portfolio includes three clinical-stage candidates, AXS-05, AXS-02, and AXS-06, which Axsome Therapeutics is developing for multiple indications. Axsome Therapeutics is conducting a Phase 3 trial with AXS-05 in treatment resistant depression, or TRD, which the company refer to as the STRIDE-1 study, and a Phase 2/3 trial in agitation in patients with Alzheimer’s disease, or AD, which the company refer to as the ADVANCE-1 study. Axsome Therapeutics is also conducting a Phase 3 trial with AXS-02 in complex regional pain syndrome, or CRPS, which the company refer to as the CREATE-1 study, ...

MGWFF: Maple Leaf Green World Inc Analysis and Research Report

2018-02-05 - Asif

Business Overview and Development Maple Leaf is incorporated in Alberta, Canada, with common shares listed on the TSX Venture Exchange (“TSXV”) under symbol MGW. The corporate office is located at 2916B 19 Street NE, Calgary, Alberta. In October 2012, Maple Leaf changed its name to Maple Leaf Green World Inc. from Maple Leaf Reforestation Inc. Maple Leaf and its subsidiaries focus on the emerging cannabis industry in North America. The Company devotes its time, effort, and capital to seek medical cannabis business opportunities, including obtaining a license to produce and sell cannabis from Health Canada pursuant to the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). Maple Leaf is also engaged in medical cannabis operations in the United States of America (“USA”), in the states of California and Nevada only. Medical Cannabis Canadian Medical Cannabis Since mid-2014 the Company has been pursuing a license to produce and sell cannabis, as dire...

GBHPF: Global Hemp Group (CNSX:GHG) Analysis and Research Report

2018-02-05 - Asif

Global Hemp Group Inc. (formerly Arris Holdings Inc.) was incorporated on October 30, 2009 in British Columbia, Canada and had its name change effective on March 24, 2014. The company’s principal activity had been exploration and development of mineral properties in prior periods and changed to agriculture and manufacturing in the industrial hemp sector on March 24, 2014 when the Company changed its name to Global Hemp Group Inc. The Company is focused on acquiring and/or joint venturing with companies across all sectors of the hemp and cannabis industries in an effort to build a "soil-to-shelf" portfolio of complementary companies that will enable GHG to capture cash flow, revenues and value from its acquisitions and establish a far greater collective valuation than GHG or the individual companies would have on their own. Management is actively looking at new projects in the hemp cultivation and cannabinoid extraction space that can be acquired or joint-ventured with, to produce...

NXTTF: Namaste Technologies Inc (CNSX:N) Analysis and Research Report

2018-02-04 - Asif

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience. Description of the business Dollinger E...

STRRF: Satori Resources Inc (TSXV:BUD) Analysis and Research Report

2018-02-03 - Asif

Satori Resources Inc. is a gold exploration company focused on exploring and developing the 100% owned Tartan Lake Gold Mine Project ("Tartan Lake") located in Flin Flon, Manitoba. The property is approximately 2,670 hectares in area and consists of 20 mineral claims. The project was a past producing asset (historical production of ~ 47,000 oz Au) which hosts a significant amount of existing development including a 450 t/d processing facility, tailings, hydro power connection to the grid, a ramp portal with approximately 2,100 metres of underground development. The Company’s activities are currently directed towards exploration and development of mineral properties located in Manitoba, Canada. Satori’s principal project is the Tartan Lake Gold Mine Project, a mineral property which hosts a past-producing underground mine. In 2010, the Project’s previous owner completed a National Instrument 43-101 (“NI 43-101”) compliant technical report which outlined mineral resources associ...

VDQSF: Vodis Pharmaceuticals (CNSX:VP) Analysis and Research Report

2018-01-31 - Asif

Vodis is one of North America’s foremost brand names in the medical and recreational marijuana business with operations in both the United States and Canada. Its master grow teams have consistently won or placed at each Canadian competition they have entered with their “VIP” brand. The Company, with facilities in British Columbia and Washington State, is also actively looking into expansion opportunities in other countries and throughout the United States. While Vodis and its subsidiaries cannot have any interest whatsoever in any proceeds as a result of production, processing or retail activities in the United States, it can license its brand, production and consulting services to approved Washington State license holders to ensure that all products produced under the Vodis Pharmaceuticals program and/or associated under the VIP brand meet or exceed Vodis-brand quality standards. The Company was incorporated on October 31, 2011. The Company is engaged in the application stage of...

WLDFF: Wildflower Marijuana (CNSX:SUN) Analysis and Research Report

2018-01-31 - Asif

Wildflower is a cannabis company focused on developing and designing branded cannabis products. Wildflower sells its CBD+ products online and to retailers throughout the US and also produces and markets its THC products in regulated cannabis jurisdictions. The Company is incorporated under the British Columbia Business Corporations Act and is a reporting issuer in British Columbia, Alberta and Ontario. Its common shares are listed for trading on the Canadian Securities Exchange under the symbol “SUN”. On November 22, 2017 the Company announced that it had won the recognition from High Times as the second best CBD product of 2017. High Times, a New York based monthly magazine founded in 1974, is the longest running and one of the leading news sources for the cannabis culture published its “10 Best CBD Products of 2017” featuring the Wildflower CBD+ Capsules as number 2, https://hightimes.com/cbd/best-cbd-products/9/, the only CBD capsule on the list. On November 14, 2017, the C...

QRSRF: Tinley Beverage Company (CNSX:TNY) Analysis and Research Report

2018-01-28 - Asif

The Tinley Beverage Company (Toronto, Canada) has developed a line of liquor-inspired, cannabis-infused beverages for use in jurisdictions throughout North America where such products are permitted. It is under contract with The Tinley Collective, a California Cooperative Corporation that is engaged in cannabis procurement and distribution within California’s medical cannabis system. Tinley’s whollyowned subsidiary, Hemplify, Inc. (Santa Monica, CA), manufactures the "Hemplify" and “Tinley’s Tonics” line of products. "Hemplify" is a line of fruit-flavored, sugar-free, vegan, drinkable supplements that contain hemp stalk extract. This extract contains terpenes and other phytoconstituents. Each product also contains 9-12x the potassium electrolyte content of major sports drinks, 200mg of Omega 3 and excellent sources of 9 vitamins, including 100% DV of Vitamin C, B12 and D. The Tinley’s Tonics squeeze supplement is a creamy, chocolate blend of hemp extract, MCT oil and lactose-reduced wh...

RSSFF: Affinor Growers (CNSX:AFI) Analysis and Research Report

2018-01-26 - Asif

Affinor is the only vertical farming technology company offering solutions for both indoor controlled growing and the greenhouse agriculture industry. The company's goal is to revolutionize greenhouse vertical farming by offering the highest plant density per square meter through the use of its patented vertical growing technology. Over the years, Affinor has developed several concepts, working models and prototypes to overcome and mitigate the inherent limitation of decreasing yields with increased density. By studying the physiological relationships between light and leaf area, light interception, temperature, humidity, and nutritional requirements, Affinor's Vertical Farming technology is designed to meet the needs plants require during their growth development in high density environments. Affinor Growers began as Affinor Resources focused on mining projects in Columbia and Canada. Realizing that agriculture will always be a major part of its global economy, it has transition...

BLOZF: Cannabix Technologies (CNSX:BLO) Analysis and Research Report

2018-01-26 - Asif

Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects use days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous. Recent developments On January 23, 2018 Cannabix Technol...

GLDFF: Golden Leaf Holdings (CNSX:GLH) Analysis and Research Report

2017-12-29 - Asif

The business of the Company is cannabis wholesale, retail and manufacturing business with operations in Nevada and Oregon, with an acquired Canadian subsidiary, which acquisition has closed as of the date of this report. In Oregon, the Company is a leading cannabis oil products company providing medical and adult users with a superior value experience. The Company also owns five retail dispensaries in Oregon. Golden Leaf leverages a strong management team with cannabis and consumer packaged goods experience. The Company is focused on developing the lowest cost production of highest quality oils through its competitive advantage rooted in economies of scale and intellectual property. Golden Leaf is dedicated to partnering with industries, communities and regulators. The Company’s branded products are sold in over half of the dispensaries in Oregon. As the adultuse market grows, the Company expects market share to increase with the growing preference for oils and edibles. The company...

SPLIF: Nutritional High International (CNSX:EAT) Analysis and Research Report

2017-12-28 - Asif

Nutritional High International Inc. On December 27, 2017 announce that Calyx Brands Inc. (“Calyx”), a leading distributor of cannabis products in California, has received a Medicinal – Distributor Temporary License from the California Bureau of Cannabis Control (“Temporary Medicinal Distributor License”). Nutritional High has entered into an agreement to purchase the business of Calyx (as announced in a press release on November 7, 2017). The Temporary Medicinal Distributor License will enable Calyx to distribute cannabis to licensed medical dispensaries beginning January 1, 2018. Jim Frazier, CEO of Nutritional High, commented – “We are excited about this development as it validates our due diligence and positions Calyx to be a major player in distributing cannabis products to the California market. We are working closely with Calyx’s management team to finalize the acquisition and propel forward Calyx’s expansion efforts in California. Beginning January 1, 2018, the new regulator...

THCBF: THC Biomed International (CNSX:THC) Analysis and Research Report

2017-12-25 - Asif

The Company’s principal business is the production and sale of medical marijuana through THC BioMed Ltd. which is licensed to produce and sell medical marijuana under the provisions of the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company also conducts research and development of the products and services related to cannabis for medical purposes. At the close of business on July 31, 2017, THC BioMed Ltd. and THC Meds Inc. were amalgamated and the name THC BioMed Ltd. was retained. History of business On February 18, 2016, THC BioMed Ltd. received its license to grow medical marijuana. On May 24, 2016 the Company’s license was amended to include the production of fresh marijuana, cannabis oil, and cannabis resin. On September 26, 2016, the Company announced that it signed a Letter of Intent to purchase 100% of Clone Shipper LLC, a US based company specializing in the packaging products used to transport live plants, for US$1,000,000. This is ...

SPRWF: Supreme Pharmaceuticals (CNSX:SL) Analysis and Research Report

2017-12-22 - Asif

Supreme Pharmaceuticals is a federally incorporated Canadian company. Supreme is focused on developing cannabis-focused businesses in the emerging global cannabis market. Management believes cannabis represents one of the world's most exciting emerging industries. Cannabis is consumed globally but in most countries consumption is still illegal. Recently, international jurisdictions have been re-evaluating their respective cannabis policies and legislation as part of a growing trend towards the legalization of medical cannabis and, in some cases, recreational cannabis. Canada first legalized cannabis for medical purposes in 2001 with the creation of the Marihuana Medical Access Regulations (the "MMAR"). In 2013, the MMAR was replaced by the Marihuana for Medical Purposes Regulations (the "MMPR"). The MMPR created a federally legal and regulated framework for commercial cultivation, distribution and sale of medical cannabis by licensed entities (a "Licensed Producer"). In 2016 the MMP...

OGRMF: Organigram Holdings (TSXV:OGI) Analysis and Research Report

2017-12-18 - Asif

Organigram Holdings is licensed as a Licensed Producer of medical marijuana, including dried cannabis and cannabis oil, under the ACMPR. Pursuant to its license, the Company is permitted to possess, produce, sell, provide, ship, deliver, transport and destroy medical marijuana, marijuana plants (including plants and seeds) and cannabis oil, in conformity with the ACMPR, and made its first shipment of medical marijuana to registered patients in September 2014. As at the date hereof, the Company has one of 32 licenses to produce and sell medical marijuana and one of 20 licenses to produce and sell cannabis oil under the ACMPR. The Company has the only license to produce and sell both medical marijuana and cannabis oil in Atlantic Canada. Moreover, management believes that the Company benefits from a number of competitive advantages which will allow it to be strategically positioned for future potential developments in the industry. The Company has entered into agreements with sever...

IVITF: Invictus MD Strategies (CNSX:IMH) Analysis and Research Report

2017-12-18 - Asif

Invictus MD is a cannabis company founded in Vancouver, Canada. Invictus MD went public December 2014. The company represent a platform of licensed producers, under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), dedicated to providing high-quality, regulated pharma-grade cannabis for medical and recreational use. The company's growers are supported by over 250 acres of buildable property with full access to its team of industry-leading horticulturists, biochemists, and project managers. Production update Acreage Pharms Ltd - West-Central, Alberta Phase 1 - Existing 6,800 sq ft purpose built concrete and steel facility 609 kg cannabis cultivation capacity per annum Level 8 vault allows for storage onsite of $31.25MM of dried cannabis The current 150-acre property can accommodate future expansion plans Invictus MD owns 100% of Acreage Pharms Phase 2 - Funded Expansion 32,000 sq ft purpose built concrete and steel faci...

TBQBF: Emerald Health Therapeutics (TSXV:EMH) Analysis and Research Report

2017-12-14 - Asif

Emerald Health Therapeutics, Inc. was incorporated pursuant to the Business Corporations Act (British Columbia) on July 31, 2007 as Firebird Capital Partners Inc. and changed its name to Firebird Energy Inc. in December 2012. On September 4, 2014, the Company completed the acquisition of all the issued and outstanding common shares of Thunderbird Biomedical Inc. (“Thunderbird”), by way of a reverse takeover (the “Transaction”) under the rules of the TSX Venture Exchange (the “TSXV”) and concurrently changed its name to T-Bird Pharma, Inc. At that time, Thunderbird became a wholly-owned subsidiary of T-Bird. In June 2015, the Company changed its name to Emerald Health Therapeutics, Inc. and Thunderbird changed its name to Emerald Health Botanicals Inc. (“Botanicals”). The Company is a publicly traded company with headquarters in Victoria, British Columbia, Canada. Common shares of the Company (the “Common Shares”) are listed on the TSXV under the trading symbol “EMH”. The Company is ...

TWMJF: Canopy Growth Corporation (TSXV:WEED) Analysis and Research Report

2017-12-14 - Asif

Canopy Growth, an early mover in the Canadian market, is a multi-brand cannabis company that believes its strong focus on and investment in brand, market and product differentiation, increased cannabis supply through Company and partner cannabis production platforms, and education, to help citizens safely, effectively and responsibly use cannabis, will create a dominant global business with the potential to generate a significant and sustained return on invested capital over the long-term. The Company’s strategy is to focus on developing and scaling to be the world’s biggest multi-platform, creator of high value branded offerings in multiple formats for medical cannabis markets in Canada and abroad where federally legal, and for regulated recreational markets when they are federally legalized. During the second quarter and since then, the Company has directed its efforts on major expansion plans to increase both capacity and capability in six provinces, so far, and six countries ...

How to Create Training and Test Data Sets for your Stock Market Machine Learning Pipeline

2017-12-11 - Wilton

One of the key components of a successful machine learning system is the Training File. The training file is a specially formatted file that is used as input into a machine learning algorithm. The machine learning algorithm uses the data in the file to "learn" how to predict success from the data. However, in order to work properly, there are some specific things you must understand. First of all, the most common machine learning algorithms are trained to predict "success." Success, of course, is whatever we define it. With stock market algos, success generally means that the stock price rose after a period of time. This takes us to our next concept. When running in production, the machine learning algorithm has no ability to see the future. So, when you create your training file, you must ensure that the features you provide are lagged. For stock market algos, you want to lag the features by your expected investment horizon. The "features" are the various items that you want ...

BLEVF: Beleave (CNSX:BE) Analysis and Research Report

2017-12-11 - Asif

Beleave Inc, formerly Stream Ventures Inc, is a Canada-based biotech company. The Company's main focus is on the production of medical marijuana. The Company's subsidiary, First Access Medical Inc, is interested in a license to cultivate and sell medical marijuana at its facility pursuant to the Marihuana for Medical Purposes Regulations outlined by Health Canada. The Company is working towards the development of patents through research with Canadian institutions as well as the research and development of cannabis-based therapies for patients, such as smoke harm reduction products, which includes portable and stationary vaporizes and accessories. Beleave Inc’s purpose built facility is located near Hamilton, Ontario. Current facility is 14,500 square feet of production space, office space, vault, security monitoring, data storage, and full IT integration and it has capacity to produce 550,000 grams of marihuana per year. Recent development Dec. 04, 2017 the company anno...

RNN: Rexahn Pharmaceuticals Analysis and Research Report

2017-12-10 - Asif

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative treatments for cancer. The company's mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. The company's clinical pipeline features three oncology product candidates in Phase II clinical development and additional compounds in pre-clinical development. The company's strategy is to continue building a significant pipeline of innovative oncology product candidates that the company intend to commercialize with partners. The company's three clinical stage drug candidates in active development are RX-3117, Supinoxin TM (RX-5902) and Archexin®. RX-3117 is a small molecule nucleoside compound that the company believe has therapeutic potential in a broad range of cancers...

APHQF : Aphria (TSXV:APH) Analysis and Research Report

2017-12-10 - Asif

Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada, Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. Aphria is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. Aphria is the first public licenced medical cannabis producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters. Pure Natures Wellness (PNW), a wholly-owned subsidiary of the Company, is licenced to produce and sell medical marijuana under the provisions of the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). PNW received its licence to produce and sell medical marijuana on November 26, 2014, followed by its licence to sell cannabis extracts on August 18, 2016. PNW’s operations are based in Leamington, ...

ACBFF : Aurora Cannabis (TSXV:ACB) Analysis and Research Report

2017-12-09 - Asif

Aurora Cannabis is a community minded, Canadian owned and operated company. Nestled in the shadow of the Rockies in Mountain View County, its plants are carefully brought to harvest in its purpose-built 55,200 square foot facility. Fed with water from the Canadian Rockies, cared for in a state-of-the-art facility designed to produce the cleanest, safest medical cannabis available on the market, we're proud of its facility, its team and its product. Cultivating, harvesting, and selling Canadian Medical Marijuana, Aurora is your best chance to experience the healing power of nature. On November 27th, 2015 Aurora was officially issued its license to sell. This marked a monumental step in the continued success and evolution of Aurora as one of Canada's top medical marijuana companies. Aurora is one of 35 licensed producers across Canada and the only one located in Alberta. Boasting the second highest square footage approved for production in Canada, Aurora was the first applicant ...

LXRP: Lexaria Bioscience Corporation (CNSX:LXX) Analysis and Research Report

2017-11-30 - Asif

The company's business plan is currently focused on the development of strategic partnerships with licensees for its patented technology in exchange for up front and/or staged licensing fees over time. Secondarily and more generally, the company continue to investigate national and international opportunities for development and distribution of the Company’s enhanced functional food and supplement product offerings; to investigate expansions and additions to its intellectual property portfolio; and, to search for additional opportunities in alternative health sectors. This includes the acquisition or development of intellectual property if and when the company believe it advisable to do so. The company announced issuance of its first patent by the U.S. Patent and Trademark Office (USPTO) on October 26, 2016 and have received a Notice of Acceptance from the Australian Patent Office with related patent issuance date June 15 2017 No. 2015274698. The company announced on November 2, 2017 a...

NMUS : Nemus Bioscience Analysis and Research Report

2017-11-30 - Asif

Nemus Bioscience is a biopharmaceutical company focused on the discovery, development, and the commercialization of cannabis-based therapeutics, or cannabinoids, through its partnership with the University of Mississippi, or UM. UM has held the only contract to cultivate cannabis for research purposes on behalf of the Federal Government since 1968, and it has significant expertise in cannabis cultivation and the extraction, separation, process and manufacture of cannabis extracts. Nemus Bioscience is currently UM's sole partner for the development and commercialization of drugs derived from cannabis extracts, or cannabinoids, and the realization of this partnership will depend on the successful navigation of the complex regulatory framework for the cultivation and handling of cannabis in the United States. Recent Events and Significant Contracts UM 5050 pro-drug agreements: On September 29, 2014, the Company executed three license agreements with UM pursuant to whi...

AGTK : Agritek Holdings Analysis and Research Report

2017-11-25 - Asif

Corporate History Agritek Holdings, Inc., was initially incorporated under the laws of the State of Delaware in 1997 under the name Easy Street Online, Inc. In 1997, the Company changed its name to Frontline Communications Corp. (“Frontline”) and operated as a regional Internet service provider (“ISP”) providing Internet access, web hosting, website design, and related services to residential and small business customers throughout the Northeast United States and, through a network partnership agreement, Internet access to customers nationwide. On April 3, 2003, the Company acquired Proyecciones y Ventas Organizadas, S.A. de C.V. (“Provo Mexico”) and in December 2003 the Company changed the name to Provo International Inc. (“Provo”). In 2008, Provo changed its name to Ebenefits Direct, Inc., which, through its wholly-owned subsidiary, L.A. Marketing Plans, LLC, engaged in the business of direct response marketing. The Company’s principal business was to market and ...

CNAB : United Cannabis Corp Analysis and Research Report

2017-11-25 - Asif

United Cannabis was originally formed on November 15, 2007 as a California corporation under the name MySkin, Inc. MySkin was engaged in the business of providing management services to a medical spa in Los Angeles, California which provided various advanced skin care services until March 31, 2014, when this business was sold to the former President of the Company. In early 2014 the company decided to exit the medical spa management business and change its focus to creating unique products which can be used to treat a wide range of diseases that can be used by patients globally. The company's products are subject to all existing marijuana laws in the United States. The company own intellectual property relating to the legalized growth, production, manufacture, marketing, management, utilization and distribution of medical and recreational marijuana and marijuana infused products. United Cannabis has entered into what the company believe are significant agreements with partners wh...

CANN : General Cannabis Corp Analysis and Research Report

2017-11-25 - Asif

The company operate in a rapidly evolving and highly regulated industry that, as has been estimated by some, will exceed $30 billion in revenue by the year 2020. General Cannabis has been and will continue to be aggressive in executing acquisitions and pursuing other opportunities that the company believe will benefit it in the long-term. Through its reporting segments, the company provide products and services to the regulated cannabis industry, which include the following: Security and Cash Transportation Services (“Security Segment”) The company provide advanced security, including on-site professionals and cash transport, to licensed cannabis cultivators and retail shops, under the business name Iron Protection Group (“IPG”), and security services to non-cannabis customers in the hospitality business, such as hotels, under the business name Mile High Protection Services (“Mile High”). The drop in wholesale prices in Colorado has negatively impacted security service...

PHOT : GrowLife Stock Analysis and Research Report

2017-11-25 - Asif

GrowLife, Inc. is incorporated under the laws of the State of Delaware and is headquartered in Kirkland, Washington. GrowLife was founded in 2012 with the Closing of the Agreement and Plan of Merger with SGT Merger Corporation. The company's goal of becoming the nation’s largest cultivation facility service provider for the production of organics, herbs and greens and plant-based medicines continues to guide its decisions. The company's mission is to measure its success by its customer’s success; serving cultivators of all sizes as a reliable business partner and its shareholders with value and trust. Through knowledgeable representatives and its e-commerce website, GrowLife provides essential and hard-to-find goods including growing media, industry-leading hydroponics equipment, organic plant nutrients, and thousands more products to specialty grow operations across the United States and Canada. The company primarily sell through its wholly owned subsidiary, GrowLife Hydroponi...

VAPE : Vape Holdings Stock Analysis and Research Report

2017-11-23 - Asif

Background On August 9, 2013, PeopleString Corporation, and its wholly-owned subsidiary, RewardString Corporation (“RewardString”), and Vape Holdings, Inc., a Nevada corporation (the “Private Company”), entered into a Merger and Reorganization Agreement (the “Agreement”) whereby the Private Company merged with RewardString, with the Private Company being the surviving entity (the “Merger”). In consideration for the merger, the shareholders of the Private Company received a total of approximately 4,684,538 shares of common stock of the merged company on a pro rata basis in exchange for 8,875 shares of the Private Company’s common stock, representing 100% of the outstanding common stock of the Private Company. The total shares of the merged company issued on a pro rata basis to the Private Company shareholders represented approximately 74.95% of the total issued and outstanding common stock of the merged company. The merger among PeopleString, RewardString and the Private ...

CBIS : Cannabis Science Stock Analysis and Research Report

2017-11-23 - Asif

Business Overview Cannabis Science, Inc. (formerly Gulf Onshore, Inc.) (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 7, 2009, the Company changed its name to Cannabis Science, Inc. Cannabis Science, Inc. is at the forefront of medical cannabis research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In summary, Cannabis Science is dedicated to the creation of cannabis-based...

UBQU : Ubiquitech Software Corporation Stock Analysis and Research Report

2017-11-23 - Asif

HISTORY Ubiquitech Software was incorporated under the laws of the State of Colorado on January 11, 2007. Until June, 2009, its business was to develop and market proprietary specialized computer software to help manage electronically stored data. The company had designed and planned to develop a software application for health care businesses known as Ubiquitech™ Enterprise Storage Manager (“UESM"). UESM was designed to provide computer data storage technicians with reporting and system problem notification. The securities of these two companies are currently being held in trust on behalf of its shareholders of record on June 29, 2009 and it is expected that these companies will be “spun-off” in the near future by former management filing a registration statement with the SEC pursuant to the Securities Act of 1933, as amended. In June 2009, control of its company changed and as a result, the company changed the focus of its business plan from the development of specialize...

CVSI : CV Sciences Stock Analysis and Research Report

2017-11-20 - Asif

CV Sciences was incorporated under the name Foreclosure Solutions, Inc. in the State of Texas on December 9, 2010. On July 25, 2013, the Company’s predecessor, CannaVest Corp., a Texas corporation (“CannaVest Texas”), merged with the Company, a wholly-owned Delaware subsidiary of CannaVest Texas, to effectuate a change in the Company’s state of incorporation from Texas to Delaware. On January 4, 2016, the Company filed a Certificate of Amendment of Certificate of Incorporation with the Secretary of State of the State of Delaware, reflecting its corporate name change to “CV Sciences, Inc.”, effective on January 5, 2016. In addition, on January 4, 2016, the Company amended its Bylaws to reflect its corporate name change to “CV Sciences, Inc.” The Company previously operated under the corporate name of CannaVest Corp. On June 8, 2016, the Company changed its trading symbol from CANV to CVSI, and continues to be traded on the OTC: QB. The change in corporate name was undertaken in conn...

AMMJ : American Cannabis Company Stock Analysis and Research Report

2017-11-20 - Asif

American Cannabis Company, Inc. and subsidiary company, Hollister & Blacksmith, Inc., doing business as American Cannabis Consulting (“American Cannabis Consulting”) are based in Denver, Colorado and operate a fully-integrated business model that features end-to-end solutions for businesses operating in the regulated cannabis industry in states and countries where cannabis is regulated and/or has been de-criminalized for medical use and/or legalized for recreational use. The Company provides advisory and consulting services specific to this industry, manufactures proprietary industry solutions including; the Satchel™, SoHum Living Soils™, Cultivation Cube™ and the High Density Cultivation System.™ The Company also sells 3rd party industry-specific products and manages a strategic group partnership that offers both exclusive and non-exclusive customer products commonly used in the industry. American Cannabis Company, Inc. is a publicly listed company quoted on the OTCQB under the symbol...

TRTC: Terra Tech Stock Analysis and Research Report

2017-11-16 - Asif

Terra Tech is a holding company with the following subsidiaries: Edible Garden Corp., a Nevada corporation (“Edible Garden”); MediFarm, LLC, a Nevada limited liability company (“MediFarm”); MediFarm I, LLC, a Nevada limited liability company (“MediFarm I”); MediFarm I Real Estate, LLC, a Nevada limited liability company (“MediFarm I RE”); MediFarm II, LLC, a Nevada limited liability company (“MediFarm II”); IVXX, LLC, a Nevada limited liability company (“IVXX LLC”); IVXX, Inc., a California corporation (“IVXX Inc.”; together with IVXX LLC, “IVXX”); Blüm San Leandro, a California corporation (“Blüm San Leandro”); Black Oak Gallery, a California corporation (“Black Oak”); GrowOp Technology Ltd., a Nevada corporation (“GrowOp Technology”); EG Transportation, LLC, a Nevada limited liability company (“EG Transportation”); and MediFarm So Cal, Inc., a California mutual benefit corporation (“MediFarm SoCal”) History and Background On Febru...

SGBY : Signal Bay Stock Analysis and Research Report

2017-11-16 - Asif

Signal Bay, Inc., a Colorado corporation and its subsidiaries provide advisory, management and analytical testing services to the emerging legalized cannabis industry. The company's three business units are described below: Signal Bay, Inc. was originally incorporated in the State of New York, December 12, 1977 under the name 3171 Holding Corporation. On February 22, 1979, the name was changed to Electronomic Industries Corp. and on February 23, 1983 the name was changed to Quantech Electronics Corp. The Company was reincorporated in the State of Colorado on December 15, 2003. On August 29, 2014, the Company completed a reverse merger with Signal Bay Research, Inc., a Nevada Corporation, and took over its operations. In September 2014, the Company changed its name from Quantech Electronics Corp. to Signal Bay, Inc. The Company has selected September 30 as its fiscal year end. Signal Bay, Inc. is domiciled in the State of Colorado, and its corporate headquarters are located in Bend,...

KAYS: Kaya Holdings Stock Analysis and Research Report

2017-11-16 - Asif

Kaya Holdings was incorporated in Delaware in 1993 under the name Gourmet Market, Inc. and has engaged in a number of businesses. Its name was changed on May 11, 2007 to Netspace International Holdings, Inc. (“Netspace”). Netspace acquired 100% of the capital stock of Alternative Fuels Americas, Inc., a Florida corporation in January 2010 in a stock for stock transaction and issued 100,000 shares of Series C convertible preferred stock to existing shareholders of the Florida corporation. The Company’s name was changed in October 2010 from Netspace International Holdings, Inc. to Alternative Fuels Americas, Inc. From 2010 through 2014 the Company was engaged in seeking to develop a biofuels business. In January 2015, the Company determined that it was in the best interests of its stockholders to discontinue its biofuel development activities, and to instead leverage its agricultural and business development experience and focus all its resources on the development of legal medical a...

FWDG : FutureWorld Corporation Stock Analysis and Research Report

2017-11-16 - Asif

FutureWorld (FWDG), a Delaware corporation, is a leading provider of advanced technologies and solutions to the global cannabis industry. FutureWorld, together with its subsidiaries, focuses on the identification, acquisition, development, and commercialization of cannabis related products and services, such as industrial Hemp. FutureWorld, through its subsidiaries, provides personal and professional THC and CBD test kits, pharmaceutical grade CBD oil solutions, SafeVape vaporizers, smart sensor technology, communication network, surveillance security, data analysis for smart cultivation and consultation for the industrial hemp and legal medicinal cannabis. The company's wireless agricultural smart sensor networks offer precision to the agriculture, irrigation systems, and greenhouses for the global cannabis and hemp industry. FutureWorld and its subsidiaries do not grow, distribute or sell marijuana. As the only Cannabis Technology Accelerator, FutureWorld will incubate and fund l...

CBDS : Cannabis Sativa Stock Analysis and Research Report

2017-11-16 - Asif

Cannabis Sativa was incorporated under the laws of Nevada in November 2005. The company acquired a wholly-owned subsidiary named Kush, a Nevada corporation, in June 2014 in exchange for shares of its common stock. Since November 2015, Kush has been spun off and is no longer a subsidiary of the Company. The company's wholly-owned subsidiary Wild Earth Naturals, Inc. ("Wild Earth") was acquired by it in July 2013 in exchange for shares of its common stock. The company acquired a 50.1% interest in its subsidiary iBudtender, Inc., including its wholly owned subsidiary iBudtender, LLC, a California limited liability company (collectively, “iBudtender”) in August of 2016 in exchange for cash and shares of its common stock. On July 27, 2017, the company acquired a 51% interest in PrestoCorp, a Delaware corporation, in exchange for shares of its common stock. From its inception through September 30, 2013, the company were engaged in the tanning salon business and operated a tanning salon ...

ACAN : AmeriCann Stock Analysis and Research Report

2017-11-16 - Asif

AmeriCann's business plan is to offer a comprehensive, turnkey package of services that includes consulting, design, construction and financing to approved and licensed marijuana operators throughout the United States. The company's business plan is based on the anticipated growth of the regulated marijuana market in the United States. AmeriCann’s team includes board members, consultants, engineers and architects who specialize in real estate development, traditional horticulture, lean manufacturing, medical research, facility construction, regulatory compliance, security, marijuana cultivation and genetics, extraction processes, and infused product development. To support local businesses that seek to serve cannabis patients in their communities the company initiated the AmeriCann Preferred Partner Program. Currently, AmeriCann has one Preferred Partner in Colorado, which is 4900 Jackson, LLC and one Preferred Partner in Massachusetts, which is Coastal Compassion, Inc. Through...

MDCL : Medicine Man Technologies Stock Analysis and Research Report

2017-11-14 - Asif

Medicine Man Technologies was incorporated on March 20, 2014, in the State of Nevada. On May 1, 2014, the company entered into an exclusive Technology License Agreement with Medicine Man Denver, Inc., f/k/a Medicine Man Production Corporation, a Colorado corporation (“Medicine Man Denver”) whereby Medicine Man Denver granted it a license to use all of their proprietary processes they have developed, implemented and practiced at its cannabis facilities relating to the commercial growth, cultivation, marketing and distribution of medical marijuana and recreational marijuana pursuant to relevant state laws and the right to use and to license such information, including trade secrets, skills and experience (present and future) (the “Medicine Man Denver License Agreement”). The company commenced its business on May 1, 2014 and currently generate revenues derived from licensing agreements with cannabis related entities, as well as sponsoring seminars offered to the cannabis industry an...

CNBX : Cannabics Pharmaceuticals Stock Analysis and Research Report

2017-11-14 - Asif

Cannabics Pharmaceuticals Inc. was incorporated in Nevada on September 15, 2004, under the name of Thrust Energy Corp. The Company was originally engaged in the exploration, exploitation, development and production of oil and gas projects within North America, but was unable to operate profitably. In May 2011, the Company changed its name to American Mining Corporation, suspending its oil and gas operations and changing its business to toll milling and refining, mineral exploration and mine development. On April 25, 2014, the Company experienced a change in control. Cannabics, Inc. (“Cannabics”) acquired a majority of the issued and outstanding common stock of the Company in accordance with stock purchase agreements by and between Cannabics and Thomas Mills (“Mills”). On the closing date, April 25, 2014, pursuant to the terms of the Stock Purchase Agreement, Cannabics purchased from Mills 20,500,000 shares of the Company’s outstanding restricted common stock for $198,000, repre...

VPCO : Healthier Choices Management Corp (NASDAQ: VPCOU) Stock Analysis and Research Report

2017-11-14 - Asif

Healthier Choices Management Corp. is a holding company focused on providing consumers with healthier daily choices with respect to nutrition and other lifestyle alternatives. The Company operates thirteen vape retail stores in the Southeast region of the United States of America. The Company offers e-liquids vaporizers and related products through its vape retail stores. The Company sold its wholesale business on July 31, 2016. The sale of the wholesale business was not contemplated prior to July 1, 2016. The sale of the wholesale business qualifies as a discontinued operation and accordingly the Company has excluded results for the wholesale business operations from the Company’s continuing operations in the unaudited consolidating Statements of Operations for all periods presented. On June 1, 2016, the Company acquired the business assets of Ada’s Whole Food Market LLC, a natural and organic grocery store, through its wholly owned subsidiary Healthy Choice Markets, Inc. The groc...

SRNA : Surna Stock Analysis and Research Report

2017-11-13 - Asif

Surna develop, design, and distribute cultivation technologies for controlled environment agriculture (“CEA”). The company's customers include state-regulated cannabis cultivation facilities as well as traditional indoor agricultural facilities, including organic herb and vegetable producers. The company's technologies include a comprehensive line of application-specific lighting, environmental control, air sanitation, and cultivation facilities. These technologies are designed to meet the specific environmental conditions required for CEA and reduce energy and water consumption. In addition, Surna offers mechanical design services specific to hydronic cooling, including mechanical equipment and piping design. The company's standard CEA project consists of small chillers, fan-coils, and dehumidifiers, the major equipment items which the company manufacture. Other required equipment items typically consist of large chillers, pumps, air separators and expansion tanks which the compan...

FVE : Five Star Senior Living Stock Analysis and Research Report

2017-11-12 - Tom

FIVE STAR SENIOR LIVING PROFILE Five Star Senior Living is a corporation formed under the laws of the State of Maryland in 2001. Five Star Senior Living operates senior living communities, including independent living communities, assisted living communities and skilled nursing facilities, or SNFs. As of December 31, 2016, Five Star Senior Living operated 283 senior living communities located in 32 states with 31,830 living units, including 253 primarily independent and assisted living communities with 29,229 living units and 30 SNFs with 2,601 living units. As of December 31, 2016, Five Star Senior Living owned and operated 26 communities (2,703 living units), Five Star Senior Living leased and operated 189 communities (20,339 living units) and Five Star Senior Living managed 68 communities (8,788 living units). Its 283 senior living communities included 10,772 independent living apartments, 16,179 assisted living suites and 4,879 skilled nursing beds. The foregoing numbers...

STLY : Stanley Furniture Stock Analysis and Research Report

2017-11-11 - Tom

Stanley Furniture Profile Established in 1924, Stanley Furniture is a leading design, marketing and overseas sourcing resource in the middle-to-upscale segment of the wood residential furniture market. Stanley Furniture offers a diversified product line supported by an overseas sourcing model. Stanley Furniture markets its brands through a network of brick-and-mortar furniture retailers, online retailers and interior designers worldwide. Stanley Furniture also markets and sells directly to the consumer through a localized approach to ecommerce order fulfillment through Stanley Furniture’s brick-and-mortar customers. Stanley Furniture was incorporated in Delaware in 1984. Products Stanley Furniture’s products are marketed as fashionable wood residential home furnishings that differentiate from other products in the market through styling execution as well as wide selections for the entire home including dining, bedroom, living room, home office, home entertainm...

NWBO : Northwest Biotherapeutics Stock Analysis and Research Report

2017-11-11 - Asif

The Company is focused on developing personalized immune therapies for cancer. Northwest Biotherapeutics has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company’s lead product, DCVax®-L, is designed to treat solid tumor cancers in which the tumor can be surgically removed. This product in an ongoing Phase III trial for newly diagnosed Glioblastome multiforme (GBM). 331 patients have been enrolled in the trial, and enrollment is closed. The Company is continuing to collect data “events” in the Phase III trial, and the data set is gradually maturing. The Company is also working on preparations for Phase II trials of DCVax-L for other indications. The Company’s second product, DCVax®-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed, and included treatment of a diverse range of cancers. The Company is working on preparations for P...

RTTR : Ritter Pharmaceuticals Stock Analysis and Research Report

2017-11-11 - Asif

Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Ritter Pharmaceuticals is advancing human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have a meaningful impact on a patient’s health. The company completed a Phase 2a clinical trial of its leading product candidate, RP-G28, an orally administered, high purity oligosaccharide in November 2011. The company completed a Phase 2b/3 multi-center, randomized, double-blind, placebo-controlled, parallel group trial of RP-G28 in October 2016. The purpose of the trial was to evaluate the safety, efficacy and tolerability of two dosing regimens of RP-G28 in patients with moderate to severe lactose intolerance symptoms. Enrollment was initiated in March 2016 and completed in August 2016, achieving its projected enrollment time pe...

IMMU : Immunomedics Stock Analysis and Research Report

2017-11-11 - Asif

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The company's advanced proprietary technologies allow it to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, Immunomedics has built a pipeline of six clinical-stage product candidates. The company believe that each of its antibodies has therapeutic potential either when administered as a naked antibody or when conjugated with chemotherapeutics, therapeutic radioisotopes (radiolabeled), cytokines or other toxins to create unique and potentially more effective treatment options. The attachment of various compounds to antibodies is intended to allow the delivery of these therapeutic agents to tumor sites with better specificity than conventional chemothe...

AVGR : Avinger Stock Analysis and Research Report

2017-11-10 - Asif

Avinger is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease, or PAD. Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The company's mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its Lumivascular platform, the only intravascular image-guided system available in this market. The company manufacture and sell a suite of products in the United States and select international markets. The company's current products include its Lightbox imaging console, as well as its Wildcat, Kittycat 2, and the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion, or CTO, and Pantheris, its image-guided atherectomy ...

CYCC : Cyclacel Pharmaceuticals Stock Analysis and Research Report

2017-11-10 - Asif

Through the second quarter of 2017, its focus has been on its transcriptional regulation program where Cyclacel Pharmaceuticals is evaluating its cyclin dependent kinase, or CDK, inhibitor and its DNA damage response, or DDR, program, in which Cyclacel Pharmaceuticals is evaluating sapacitabine in combination with its CDK inhibitor seliciclib in solid tumors in a Phase1/2 study. Additionally, Cyclacel Pharmaceuticals is completing the analysis of data from SEAMLESS, the Phase 3 study in acute myeloid leukemia, (“AML”) and have closed the last remaining clinical trial sites. Transcriptional Regulation Program, CDK inhibitors Cyclacel Pharmaceuticals is progressing clinical development of its CDK inhibitor CYC065 in an ongoing, first-in-human, Phase 1 trial in patients with advanced solid tumors. CDKs are a family of enzymes first discovered as regulators of the cell cycle, but now understood to also provide pivotal functions in the regulation of transcription, DNA repair...

TENX : Tenax Therapeutics Stock Analysis and Research Report

2017-11-10 - Asif

Tenax Therapeutics was originally formed as a New Jersey corporation in 1967 under the name Rudmer, David & Associates, Inc., and subsequently changed its name to Synthetic Blood International, Inc. Effective June 30, 2008, the company changed the domiciliary state of the corporation to Delaware and changed the company name to Oxygen Biotherapeutics, Inc. On September 19, 2014, the company changed the company name to Tenax Therapeutics, Inc. Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market. On November 13, 2013, through its wholly owned subsidiary, Life Newco, Inc., or Life Newco, the company acquired a license granting Life Newco an exclusive, sublicenseable right in the United States and Canada to develop and commercialize pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion / 5ml vial, for use in the reduction of morbidity and mor...

FATE : Fate Therapeutics Stock Analysis and Research Report

2017-11-10 - Asif

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. Fate Therapeutics is developing first-in-class cell therapy product candidates based on a simple notion: the company believe that better cell therapies start with better cells. To create better cell therapies, the company use a therapeutic approach that the company generally refer to as cell programming. For certain of its cell therapy product candidates, the company use pharmacologic modulators, such as small molecules, to enhance the biological properties and therapeutic function of cells ex vivo before its product candidates are administered to a patient. In other cases, the company use human induced pluripotent stem cells “iPSCs”, generate a master iPSC line having preferred biological properties and direct the fate of the iPSC line to create a clonal population of its cell therapy product candidate. The company beli...

CPRX : Catalyst Pharmaceuticals Stock Analysis and Research Report

2017-11-10 - Asif

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. The company currently have three drug candidates in development: Firdapse® In October 2012, the company licensed the North American rights to Firdapse®, a proprietary form of amifampridine phosphate, or chemically known as 3,4-diaminopyridine phosphate, from BioMarin Pharmaceutical Inc. (BioMarin). In August 2013, the company were granted “breakthrough therapy designation” by the U.S. Food & Drug Administration (FDA) for Firdapse® for the treatment of patients with Lambert-Eaton Myasthenic Syndrome, or LEMS, a rare and sometimes fatal autoimmune disease characterized by muscle weakness. Further, the FDA has previously granted Orphan Drug Designation for Firdapse® for the treatment of patients with LEMS, Congenital Myasthenic Syndromes, or CMS, and Myasthenia Gravis (MG). ...

AMDA : Amedica Corporation Stock Analysis and Research Report

2017-11-10 - Asif

Amedica Corporation is a materials company focused on developing, manufacturing and selling silicon nitride ceramics that are used in medical implants and in a variety of industrial devices. At present, the company commercialize silicon nitride in the spine implant market. The company believe that its silicon nitride manufacturing expertise positions it favorably to introduce new and innovative devices in the medical and non- medical fields. The company also believe that Amedica is the first and only company to commercialize silicon nitride medical implants. Amedica has received 510(k) regulatory clearance in the United States, a CE mark in Europe, and ANVISA approval in Brazil for a number of its devices that are designed for spinal fusion surgery. To date, more than 28,000 of its silicon nitride devices have been implanted into patients, with an 8-year successful track record. The company intend to file an FDA 510(k) submission for clearance in the United States of a novel compos...

AXON : Axovant Sciences Stock Analysis and Research Report

2017-11-09 - Asif

Axovant Sciences is a clinical-stage biopharmaceutical company dedicated to advancing treatments for patients with life-altering neurologic conditions. To date, its primary focus has been on developing intepirdine, an orally administered antagonist of the 5-HT 6 receptor, for the treatment of Alzheimer's disease and dementia with Lewy bodies, or DLB, and its second product candidate, nelotanserin, a potent and highly selective inverse agonist of the 5-HT 2A receptor, for the treatment of visual hallucinations in patients with Lewy body dementia, or LBD, movement disorder symptoms in patients with DLB and REM behavior disorder, or RBD, in patients with LBD. In September 2017, the company announced that the Phase 3 MINDSET clinical trial of 35 mg intepirdine in patients with mild-to-moderate Alzheimer's disease who were receiving background donepezil therapy did not meet its co-primary efficacy endpoints. Axovant Sciences is continuing to advance the products in its pipeline, focusing on...

ETRM : EnteroMedics Stock Analysis and Research Report

2017-11-09 - Asif

EnteroMedics is a medical device company focused on the development and commercialization of technology to treat obesity and metabolic diseases. The vBloc®System, its initial product, is a U.S. Food and Drug Administration (FDA)-approved pacemaker-like device that delivers vBloc® Neurometabolic Therapy (vBloc Therapy) to help patients feel full and eat less by intermittently blocking hunger signals on the vagus nerve. The company's therapy limits the expansion of the stomach, helps control hunger sensations between meals, reduces the frequency and intensity of stomach contractions and produces a feeling of early and prolonged fullness. The company believe the vBloc System offers obese patients a minimally-invasive treatment that can result in significant, durable and sustained weight loss. The company believe that its vBloc System allows bariatric surgeons to offer a new option to obese patients who are concerned about the risks and complications associated with currently availabl...

OMER : Omeros Corporation Stock Analysis and Research Report

2017-11-09 - Asif

Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The company's drug product OMIDRIA ® is marketed in the U.S. for use during cataract surgery or intraocular lens, or IOL, replacement. OMIDRIA is part of its proprietary PharmacoSurgery ® platform, which is designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. The company's PharmacoSurgery platform is based on low-dose combinations of FDA-approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery. In its pipeline Omer...

ZSAN : Zosano Pharma Corporation Stock Analysis and Research Report

2017-11-09 - Asif

Zosano Pharma Corporation and its subsidiary is a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied Microarray (ADAM) technology. The company recently announced positive results from its ZOTRIP study that evaluated M207, which is its proprietary formulation of zolmitriptan delivered via its ADAM technology, as an acute treatment for migraine. Zosano Pharma is focused on developing products where rapid administration of established molecules with known safety and efficacy profiles provides an increased benefit to patients, for markets where patients remain underserved by existing therapies. The company anticipate that many of its current and future development programs may enable it to utilize a regulatory pathway that would streamline clinical development and accelerate the path towards commercialization. ADAM is its proprietary, investigational technology platform d...

TGTX : TG Therapeutics Stock Analysis and Research Report

2017-11-09 - Asif

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, TG Therapeutics is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 (interleukin-1 receptor-associated kinase 4) inhibitors, BET (Bromodomain an...

EARS : Auris Medical Holding Stock Analysis and Research Report

2017-11-09 - Asif

Auris Medical is a clinical-stage biopharmaceutical company focused on the development of novel products for the treatment of inner ear disorders. The company's most advanced product candidates are in Phase 3 clinical development. Keyzilen® (AM-101) is being developed for the treatment of acute inner ear tinnitus and has received fast track designation from the FDA. AM-111 is being developed for the treatment of acute inner ear hearing loss and has been granted orphan drug status by the FDA and the EMA and has been granted fast track designation by the FDA. AM-125 is being developed for the treatment of vestibular disorders. In addition, Auris Medical is pursuing early stage projects for the treatment of tinnitus and rhinology. The company believe Auris Medical is currently the clinically most advanced company working on inner ear therapeutics. The company believe that Keyzilen® and AM-111 are the only drug candidates that have demonstrated positive efficacy in randomized placebo-c...

CALA : Calithera Biosciences Stock Analysis and Research Report

2017-11-09 - Asif

Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule oncology drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Tumor metabolism and immuno-oncology (“I-O”) have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients. Calithera Biosciences is developing agents that take advantage of the unique metabolic requirements of tumor cells and cancer-fighting immune cells such as cytotoxic T-cells. The company's lead product candidate, CB-839, is an internally discovered, first-in-class oral inhibitor of glutaminase, a critical enzyme in tumor cells. CB-839 administered as a single agent has resulted in clinical responses in renal cell cancer and acute myeloid leukemia. Calithera Biosciences is cu...

P : Pandora Media Stock Analysis and Research Report

2017-11-09 - Asif

Pandora is the world’s most powerful music discovery platform, offering a personalized experience for each of its listeners wherever and whenever they want to listen to music—whether through earbuds, car speakers or home audio/video equipment. The company's vision is to be the definitive source of music discovery and enjoyment for billions of users. Pandora is available as an ad-supported service, a radio subscription service called Pandora Plus and an on-demand subscription service called Pandora Premium. The majority of its listener hours occur on mobile devices, with the majority of its revenue generated from advertising on its ad-supported service on these devices. The company offer both local and national advertisers the opportunity to deliver targeted messages to its listeners using a combination of audio, display and video advertisements. The company also generate revenue from subscriptions to Pandora Plus and Pandora Premium. Founded by musicians, Pandora also empowers artists ...

SHOP : Shopify Stock Analysis and Research Report

2017-11-09 - Asif

Shopify provides the leading cloud-based, multi-channel commerce platform designed for small and medium-sized businesses. Merchants use its software to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts, and marketplaces. As the number of channels over which merchants transact continues to expand, the importance of a multi-channel platform that is both fully integrated and easy to use increases. The Shopify platform provides merchants with a single view of their business and customers across all of their sales channels and enables them to manage products and inventory, process orders and payments, ship orders, build customer relationships and leverage analytics and reporting all from one integrated back office. Commerce transacted over mobile devices continues to grow more rapidly than desktop transactions. For several years Shopify has focused on enabling mobile commerce and its merchants ...

OTIC : Otonomy Stock Analysis and Research Report

2017-11-08 - Asif

Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. OTIPRIOâ (ciprofloxacin otic suspension) is approved in the United States for use during tympanostomy tube placement (TTP) surgery in pediatric patients, has achieved positive pivotal trial results in patients with acute otitis externa (AOE), and has completed a successful Phase 2 trial in patients with acute otitis media with tubes (AOMT). OTO-104 is a steroid in development for the treatment of Ménière’s disease and other severe balance and hearing disorders. Two Phase 3 trials in Ménière’s disease patients are underway with results expected during the second half of 2017, and a Phase 2 trial has been initiated in patients at risk for cisplatin-induced hearing loss. OTO-311 is a N-Methyl-D-Aspartate (NMDA) receptor antagonist for the treatment of tinnitus that has completed a Phase 1 clinical safety trial with a Phase 2 trial expect...

BZUN : Baozun Stock Analysis and Research Report

2017-11-08 - Asif

Baozun Inc. is an exempted company incorporated under the laws of the Cayman Islands on December 17, 2013. The company changed its holding company’s name from Baozun Cayman Inc. to Baozun Inc. in March 2015. Baozun is a holding company and operate its business through its wholly-owned subsidiaries and a PRC consolidated VIE. The company commenced operations to provide brand e-commerce solutions in China in August 2007 through Shanghai Baozun, a PRC limited liability company founded by its CEO Mr. Vincent Wenbin Qiu, its COO Mr. Junhua Wu, Mr. Michael Qingyu Zhang and several other individual investors, or collectively, the Founding Shareholders. Shanghai Baozun, its wholly-owned subsidiary, provides integrated brand-e-commerce solutions to its brand partners, including IT services, store operations, digital marketing, customer services, warehousing and fulfillment. In March 2010, the company incorporated its wholly-owned subsidiaries, Shanghai Bodao E-Commerce Limited, or Shang...

ARGS: Argos Therapeutics Stock Analysis and Research Report

2017-11-08 - Asif

Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary precision immunotherapy technology platform called Arcelis. The company's most advanced product candidate is rocapuldencel-T, which Argos Therapeutics is developing for the treatment of metastatic renal cell carcinoma, or mRCC, and other cancers. Argos Therapeutics is currently conducting a pivotal Phase 3 clinical trial of rocapuldencel-T plus sunitinib or another therapy for the treatment of newly diagnosed mRCC under a special protocol assessment, or SPA, with the Food and Drug Administration, or FDA. The company refer to this trial as the ADAPT trial. The company dosed the first patient in the ADAPT trial in May 2013 and completed enrollment of the ADAPT trial in July 2015. In February 2017, the independent data monitoring committee, or the IDMC, for the ADAPT trial recomm...

AKAO : Achaogen Stock Analysis and Research Report

2017-11-08 - Asif

Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterial treatments against multi-drug resistant (“MDR”) gram-negative infections. Achaogen is researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (“cUTI”), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (“CRE”). In 2013, the Centers for Disease Control and Prevention identified CRE as a “nightmare bacteria” and an immediate public health threat that requires “urgent and aggressive action” and in 2017 the World Health Organization identified CRE as a Global Priority 1 Pathogen: Critical Need for Research and Development of New Antibiotics. On December 12, 2016, the company announced positive data from its two Phase 3 clinical trials for plazomicin. The firs...

MOMO : Momo Stock Analysis and Research Report

2017-11-07 - Asif

The company started its operations in July 2011 when its founders established Beijing Momo in China. In order to facilitate foreign investment in its company, the company incorporated its holding company under the name of Momo Technology Company Limited in the British Virgin Islands in November 2011. In July 2014, Momo Technology Company Limited was redomiciled in the Cayman Islands as an exempted company registered under the laws of the Cayman Islands, and was renamed Momo Inc. The following outlines other major changes to its corporate structure in the past years. In December 2011, the company established Momo HK, a wholly-owned subsidiary, in Hong Kong. In March 2012, Beijing Momo IT was established as a wholly-owned subsidiary of Momo HK. In April 2012, the company underwent a corporate restructuring, whereby the company obtained effective control over Beijing Momo through a series of contractual arrangements among Beijing Momo, Beijing Momo IT and the shareholders of B...

ATNM : Actinium Pharmaceuticals Stock Analysis and Research Report

2017-11-07 - Asif

Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for safer myeloablation and conditioning of the bone marrow prior to a bone marrow transplant (“BMT”) and for the targeting and killing of cancer cells. Actinium Pharmaceuticals is currently conducting clinical trials for its three product candidates, Iomab-B, Actimab-A and Actimab-M, as well as performing research on other potential drug candidates utilizing its proprietary alpha-particle technology platform. The company's most advanced product candidate, Iomab-B, is comprised of an anti-CD45 monoclonal antibody labeled with iodine-131 (“I-131”). Actinium Pharmaceuticals is currently conducting a pivotal Phase 3 trial of Iomab-B for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (“AML”) age 55 and older. A bone marrow transplant is a potentially curative ...

ATOS : Atossa Genetics Stock Analysis and Research Report

2017-11-07 - Asif

Atossa Genetics is a clinical-stage pharmaceutical company focused on developing novel, proprietary therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company currently have three programs underway: two using its proprietary endoxifen (oral and topical formulations) and the other using its patented microcatheter technology. The company's proprietary oral and topical forms of endoxifen are the subject of a comprehensive Phase 1 clinical study in healthy women in Australia. The company's patented microcatheter technology is in a Phase 2 clinical study that is also currently enrolling patients. Approximately one in eight women will be diagnosed with breast cancer during their lifetime. Every two minutes an American woman is diagnosed with breast cancer; 40,000 die each year. Tamoxifen has been widely used for over 30 years to both treat and prevent breast cancer. Additional research has shown that it is the metabolites of tamoxifen, o...

IMUC : ImmunoCellular Therapeutics Stock Analysis and Research Report

2017-11-07 - Asif

ImmunoCellular Therapeutics, Ltd. and its subsidiaries is a biotechnology company that is seeking to develop and commercialize new therapeutics to fight cancer using the immune system. ImmunoCellular Therapeutics is primarily engaged in the acquisition of certain intellectual property, together with development of its product candidates and the recent clinical testing for its immunotherapy product candidates, and has not generated any recurring revenues. In June 2017, the company announced that the company were unable to secure sufficient additional financial resources to complete the phase 3 registration trial of ICT-107, its patient-specific, dendritic cell-based immunotherapy for patients with newly diagnosed glioblastoma, which was previously its lead product candidate. As a result, the company suspended further patient randomization in the ICT-107 trial while the company continue to seek a collaborative arrangement or acquisition of its ICT-107 program. The suspension of the ph...

INFI : Infinity Pharmaceuticals Stock Analysis and Research Report

2017-11-07 - Asif

Infinity Pharmaceuticals is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity Pharmaceuticals is focusing its efforts on advancing IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma. Preclinical research has demonstrated that PI3K-gamma is highly expressed in tumor-associated macrophages and that blockade of PI3K-gamma signaling by treatment with IPI-549 results in a reprogramming of macrophages in the tumor microenvironment from the M2, or pro-tumor, phenotype to the M1, or anti-tumor, phenotype. This shift increased the number and activity of anti-tumor T cells that can attack the tumor and also increased the production of pro-inflammatory cytokines, which can further stimulate an anti-tumor immune response. Preclinical data from multiple solid tumor models demonstrated that IPI-549 was active as a monothe...

VSAR : Versartis Stock Analysis and Research Report

2017-11-07 - Asif

Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing a novel long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency, or GHD, an orphan disease. A key limitation to current recombinant human growth hormone, or rhGH, products is that they impose the burden of daily injections over multiple years, often resulting in poor adherence, which in turn can lead to suboptimal treatment outcomes in GHD patients. Despite this limitation, global annual sales from currently marketed rhGH products have grown to more than $3.0 billion in 2015. Based on market research, the company believe that the market for rhGH products can continue to grow up to $4.0 billion following the launch of long-acting rhGH therapies. Somavaratan is a fusion protein consisting of rhGH and a proprietary half-life extension technology known as XTEN®. Somavaratan is intended to reduce the burden of daily treatment by requiring significa...

TRXC : TransEnterix Stock Analysis and Research Report

2017-11-07 - Asif

TransEnterix, Inc. is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical challenges associated with current laparoscopic and robotic options. TransEnterix is focused on the commercialization and further development of its Senhance™ Surgical Robotic System (formerly known as the ALF-X ® Surgical Robotic System) (the “Senhance System”), a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology. The Senhance System has been granted a CE Mark in Europe for laparoscopic abdominal and pelvic surgery, as well as limited thoracic operations excluding cardiac and vascular surgery, but is not available for sale in the U.S. TransEnterix has also developed the SurgiBot™ System (the “SurgiBot System”), a single-port, robotically enhanced laparoscopic surgical platform. The SurgiBot System is not available for sale in any market. The Senhance...

BIOA : BioAmber Stock Analysis and Research Report

2017-11-07 - Asif

BioAmber is an industrial biotechnology company producing renewable chemicals. The company's proprietary technology platform combines industrial biotechnology and chemical catalysis to convert biobased feedstocks into renewable chemicals that are cost-competitive replacements for petroleum-derived chemicals and are used in a wide variety of everyday products including plastics, resins, paints, food additives and personal care products. The company currently sell its first product, bio-succinic acid, to customers in a variety of chemical markets. The company produce bio-succinic acid at its facility in Sarnia, Ontario. Succinic acid can be used to manufacture a wide variety of products used every day, including plastics, food additives and personal care products, and can also be used as a building block for a number of derivative chemicals. The company believe that its low-cost production capability and its development of bio-succinic derived products including 1,4 BDO and THF, which...

SRNE : Sorrento Therapeutics Stock Analysis and Research Report

2017-11-04 - Asif

At its core, Sorrento Therapeutics is an antibody-centric company and leverage its proprietary G-MAB™ library and targeted delivery modalities to generate the next generation of cancer therapeutics. The company's validated fully human antibodies include PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT and CD137 among others. The company's vision is to leverage these antibodies in conjunction with proprietary targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include proprietary antibody drug conjugates (“ADCs”), bispecific approaches, as well as TCR-like antibodies. With LA Cell, Inc. (“LA Cell”), its joint venture with City of Hope, its objective is to become the global leader in the development of antibodies against intracellular targets such as STAT3, mutant KRAS, MYC, p53 and TAU. Additionally, Sorrento Therapeutics has acquired and are assessing the regulatory and strategic path forward for its portfolio of late ...

KTOS : Kratos Defense & Security Solutions Stock Analysis and Research Report

2017-11-04 - Asif

Kratos Defense is a mid-size government contractor at the forefront of the DoD’s Third Offset Strategy. Kratos Defense is a leading technology, intellectual property and proprietary product and solutions company focused on the U.S. and its allies’ national security. A key element of its business plan is to make Company-funded investments related to key platforms, products and systems, so that the company own the related intellectual property. Kratos Defense is a demonstrated leader in innovation and rapidly designing, developing, demonstrating, and fielding leading technology products and systems at an affordable cost. Kratos Defense is an industry leader in high performance, jet powered, unmanned aerial drone target systems used to test weapon systems and to train the warfighter, and a provider of high performance unmanned combat aerial systems for force multiplication and amplification. Kratos Defense is also an industry leader in satellite communications, microwave electronics, cybe...

CRMD : CorMedix Stock Analysis and Research Report

2017-11-04 - Asif

CorMedix Inc. and Subsidiary, is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company's primary focus is to develop its lead product candidate, Neutrolin® (also known as CRMD003), for potential commercialization in the U.S. and other key markets. CorMedix has in-licensed the worldwide rights to develop and commercialize Neutrolin, which is a novel anti-infective solution (a formulation of taurolidine, citrate and heparin 1000 u/ml) under development in the U.S. for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as dialysis, critical/intensive care, and oncology. Infection and thrombosis represent key complications among critical care/ intensive care and cancer patients with central venous catheters. These complications can lead to treatment delays and increase...

CERC : Cerecor Stock Analysis and Research Report

2017-11-04 - Asif

Cerecor is a biopharmaceutical company that is developing innovative drug candidates to make a difference in the lives of patients with neurologic and psychiatric disorders. The company's lead drug candidate is CERC-301, which the company currently intend to explore as a novel treatment for orphan neurologic indications. The company also have two pre-clinical stage compounds, CERC-611 and CERC-406. The company's portfolio of product candidates is summarized below: CERC-301: Orphan Neurologic Diseases. CERC‑301 belongs to a class of compounds known as antagonists of the N‑methyl‑D‑aspartate, or NMDA, receptor, a receptor subtype of the glutamate neurotransmitter system that is responsible for controlling neurologic adaptation. The company believe CERC‑301 specifically blocks the NMDA receptor subunit 2B, or NR2B. Cerecor has conducted two Phase 2 studies with this drug candidate as a potential adjunctive treatment for major depressive disorders, or MDD, in which the company obs...

GSAT : Globalstar Stock Analysis and Research Report

2017-11-04 - Asif

Mobile Satellite Services Business Globalstar, Inc. (“we,” “us” or the “Company”) provides Mobile Satellite Services (“MSS”) including voice and data communications services globally via satellite. By providing wireless communications services in areas not served or underserved by terrestrial wireless and wireline networks and in circumstances where terrestrial networks are not operational due to natural or man-made disasters, the company seek to meet its customers' increasing desire for connectivity. The company offer voice and data communication services over its network of in-orbit satellites and its active ground stations (“gateways”), which the company refer to collectively as the Globalstar System. The company currently provide the following communications services via satellite. These services are available only with equipment designed to work on its network: two-way voice communication and data transmissions ("Duplex") using mobile or fixed devices; and one-w...

AABA : Altaba Stock Analysis and Research Report

2017-11-04 - Asif

Yahoo! Inc (now Altaba), together with its consolidated subsidiarie, is a guide to digital information discovery, focused on informing, connecting, and entertaining its users through its search, communications, and digital content products. By creating highly personalized experiences, the company help users discover the information that matters most to them around the world—on mobile or desktop. The company create value for advertisers with a streamlined, simple advertising technology that leverages Yahoo’s data, content, and technology to connect advertisers with their target audiences. Advertisers can build their businesses through advertising to targeted audiences on its online properties and services (“Yahoo Properties”) and a distribution network of third-party entities (“Affiliates”) who integrate its advertising offerings into their websites or other offerings (“Affiliate sites”). The company's revenue is generated principally from search and display advertising. Altaba is...

CLSN : Celsion Corporation Stock Analysis and Research Report

2017-11-04 - Asif

Celsion is a fully-integrated development stage oncology drug company focused on advancing a portfolio of innovative cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA based therapies. The company's lead product candidate is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in a Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). Second in its pipeline is GEN-1, a DNA-mediated immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies providing the basis for the future development of a range of therapeutics for difficult-to-treat forms of cancer including: Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat and Th...

TWTR : Twitter Stock Analysis and Research Report

2017-11-04 - Asif

Twitter is the best and fastest place to see what is happening and what people are talking about all around the world. Every day, instances of breaking news, entertainment, sports, politics, big events and everyday interests happen first on Twitter. Twitter is where the full story unfolds with all the live commentary and where live events come to life unlike anywhere else. The company's primary service can be accessed on a variety of mobile devices, at twitter.com and via SMS. In 2016, the company focused on positioning Twitter for long-term sustainable growth and making progress toward GAAP profitability. Specifically, the company clearly identified who Twitter is—the best and fastest place to see what’s happening in the world and what people are talking about. The company built and shipped product features that directly improved its key audience growth and engagement metrics. The company also simplified the organization to be what the company believe is more focused and efficient...

OPGN : OpGen Stock Analysis and Research Report

2017-11-03 - Asif

OpGen was incorporated in Delaware in 2001. The Company’s headquarters are in Gaithersburg, Maryland, and its principal operations are in Gaithersburg, Maryland and Woburn, Massachusetts. The Company also has operations in Copenhagen, Denmark. The Company operates in one business segment. OpGen is a precision medicine company using molecular diagnostics and informatics to help combat infectious disease. The Company is developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The Company’s molecular diagnostics and informatics...

OPTT : Ocean Power Technologies Stock Analysis and Research Report

2017-11-03 - Asif

Nearly 70% of the earth’s surface is covered by water, with over 40% of the world’s population living within approximately 150 miles of a coast. Thousands of information gathering and/or power systems are deployed in the oceans today to increase its understanding of weather, climate change, biological processes, and marine mammal patterns and to support exploration and operations for industries such as oil and gas. Most of these systems are powered by battery, solar, wind, fuel cell, or fossil fuel generators that may be unreliable and expensive to operate while they also may be limited in their ability to deliver ample electric power. These current systems often necessitate significant tradeoffs in sensor accuracy, data processing and communications bandwidth and frequency in order to operate given limited available power. More persistent power systems requiring less maintenance, such as its systems, may have the ability to save costs over these current systems. Just as importantly, i...

OPHT : Ophthotech Corporation Stock Analysis and Research Report

2017-11-03 - Asif

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat ophthalmic diseases, with a focus on orphan and age-related retinal diseases. The company currently have two product candidates, Zimura® (avacincaptad pegol), an anti-complement factor C5 aptamer, and Fovista® (pegpleranib), an anti-platelet derived growth factor, or PDGF, aptamer. Prior to 2017, the Company's primary focus was on developing Fovista and Zimura for various types of age-related macular degeneration, or AMD, which is a disorder of the central portion of the retina, known as the macula, that may result in blindness. In December 2016, the company announced that two of its three pivotal, Phase 3 clinical trials for Fovista in combination with the anti-vascular endothelial growth factor, or anti-VEGF, drug Lucentis® (ranibizumab) for the treatment of wet AMD, failed to meet their primary endpoint. The company announced in early 2017 that the company had engaged a financia...

CIE : Cobalt International Energy Stock Analysis and Research Report

2017-11-03 - Asif

Cobalt International Energy is an independent exploration and production company with operations in the deepwater U.S. Gulf of Mexico and offshore Angola and Gabon in West Africa. In the U.S. Gulf of Mexico, Cobalt International Energy has four discoveries: North Platte, Shenandoah, Anchor and Heidelberg. Heidelberg began initial production in January 2016, and North Platte, Shenandoah and Anchor are currently being appraised. In Angola, Cobalt International Energy has made seven aggregate discoveries offshore Angola on Blocks 20 (Orca, Zalophus, Golfinho and Lontra) and 21 (Cameia, Bicuar and Mavinga). The company also have a non–operated interest in the Diaba block offshore Gabon, where Cobalt International Energy has one discovery (Diaman). Operational Highlights Net production from Heidelberg averaged approximately 3,450 barrels of oil equivalent per day (“boepd”) during the three months ended September 30, 2017, and is currently producing approximately 3,400 boepd...

LODE : Comstock Mining Stock Analysis and Research Report

2017-11-03 - Asif

The Company is a Nevada-based, gold and silver mining exploration and development company with extensive, contiguous property in the historic Comstock and Silver City mining districts (collectively, the “Comstock District”). The Comstock District is located within the western portion of the Basin and Range Province of Nevada, between Reno and Carson City. The Company began acquiring properties and developing projects in the Comstock District in 2003. Since then, the Company has consolidated a substantial portion of the historic Comstock District, secured permits, built an infrastructure and brought exploration projects into production. The Company’s headquarters, technical resources, mine operations and heap leach processing facility are located in Storey County, Nevada, at 1200 American Flat Road, approximately three miles south of Virginia City, Nevada and 30 miles southeast of Reno, Nevada. The Company now owns or controls approximately 9,284 acres of mining claims and parcels in...

BABA : Alibaba Group Holding Stock Analysis and Research Report

2017-11-03 - Asif

Alibaba Group Holding Limited is a Cayman Islands holding company established under the Companies Law of the Cayman Islands (as amended) on June 28, 1999, and the company conduct its business in China through its subsidiaries and variable interest entities. The company's ADSs are listed on the NYSE under the symbol "BABA." The company's significant subsidiaries, as that term is defined under Section 1-02 of Regulation S-X under the Securities Act, include the following entities: Taobao Holding Limited, an exempted company incorporated with limited liability under the laws of the Cayman Islands, which is its wholly-owned subsidiary and the indirect holding company of the PRC subsidiaries relating to Taobao Marketplace and Tmall. Taobao China Holding Limited, a Hong Kong limited liability company, which is the direct wholly-owned subsidiary of Taobao Holding Limited and the direct holding company of the PRC subsidiaries relating to Taobao Marketplace and Tmall and operating en...

ANLDF : Anfield Resources (TSXV: ARY) Stock Analysis and Research Report

2017-11-01 - Tom

Anfield Resources Profile Anfield Resources is a uranium development and near-term production company that is committed to becoming a top-tier energy-related fuels supplier by creating value through sustainable, efficient growth in its energy metals assets. With the recent acquisition of 24 uranium projects in Wyoming, along with a Resin Processing Agreement to complement its existing conventional uranium mill and near-term production assets, Anfield is well-positioned to benefit from the growing global demand for energy. Anfield Resources’ intent is twofold: Advance its Wyoming properties in order to leverage the Resin Processing Agreement between Anfield and Uranium One Restart its Shootaring Canyon Mill in Utah to process nearby uranium resources. As well, the potential development of vanadium assets is being evaluated. Corporate Strategy Participate in conventional uranium production to leverage larger-scale, longer-term production opportunities in ...

DYLLF : Deep Yellow Limited (ASX: DYL) Stock Analysis and Research Report

2017-10-31 - Tom

Deep Yellow Limited Profile Deep Yellow Limited is an advanced-stage uranium exploration company with a clear growth strategy to establish a multi-project global uranium development platform. Led by Paladin Energy founder John Borshoff, Deep Yellow Limited has the expertise and capability to achieve its strategy during a countercyclical period for uranium investment. Deep Yellow Limited has a cornerstone suite of projects in Namibia, a top-ranked African mining destination with a long, well regarded history of safely and effectively developing and regulating its considerable uranium mining industry. Deep Yellow Limited holds four key contiguous Exclusive Prospecting Licenses (EPLs) covering 1,590km2 within the heart of what is a world-recognized, prospective uranium province of high significance. The tenements are strategically located amongst the major uranium mines of this region -- 20km south of the Husab/Rössing deposits and 40km southwest of the Langer Heinrich depos...

ADXS : Advaxis Stock Analysis and Research Report

2017-10-31 - Asif

Advaxis is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products with the lead program in Phase 3 development. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Advaxis will continue to invest in its core clinical franchises and will also remain opportunistic based on Investigator Sponsored Trials (“ISTs”) as well as licensing opportunities. ...

HUSA : Houston American Energy Stock Analysis and Research Report

2017-10-31 - Asif

Houston American Energy Corp is an independent oil and gas company focused on the development, exploration, exploitation, acquisition, and production of natural gas and crude oil properties in the U.S. Permian Basin and Gulf Coast regions, particularly Texas and Louisiana, and in the South American country of Colombia. The company focus on early identification of, and entrance into, existing and emerging resource plays, particularly in the U.S. Permian Basin and Gulf Coast and in Colombia. The company do not operate properties but typically seek to partner with, or invest in, larger operators in the development of resources or retain interests, with or without contribution on its part, in prospects identified, packaged and promoted to larger operators. By entering these plays earlier and partnering with, investing in or promoting to, larger operators, the company believe the company can capture larger resource potential at lower cost and minimize its exposure to drilling risks and ...

SDRL : Seadrill Limited Stock Analysis and Research Report

2017-10-31 - Asif

Seadrill Limited was incorporated in Bermuda under the Companies Act on May 10, 2005 as an exempted company limited by shares. The company's shares of common stock have been listed under the symbol “SDRL” on the Oslo Stock Exchange, or the “OSE”, since November 2005 and on the NYSE since April 2010. The company's principal executive offices are located at Par-la-Ville Place, 4th Floor, 14 Par-la-Ville Road, Hamilton HM 08, Bermuda and its telephone number is +1 (441) 295-6935. Seadrill is an offshore drilling contractor providing worldwide offshore drilling services to the oil and gas industry. The company's primary business is the ownership and operation of drillships, semi-submersible rigs and jack-up rigs for operations in shallow-, mid-, deep-, and ultra-deepwater areas, and in benign and harsh environments. The company contract its drilling units primarily on a dayrate basis to drill wells for its customers, who are oil super-majors and major integrated oil and gas companies, ...

ATRS : Antares Pharma Stock Analysis and Research Report

2017-10-31 - Asif

Antares Pharma, Inc. is an emerging, specialty pharmaceutical company that focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its strategy is to identify new or existing approved drug formulations and apply its drug delivery technology to enhance the drug compounds and delivery methods. The company develop, manufacture and commercialize, for itself or with partners, novel therapeutic products using its advanced drug delivery systems that are designed to help improve safety and efficacy, reduce side effects, and enhance patient comfort and adherence. Its subcutaneous injection technology platforms include the VIBEX® pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-dose pen injectors for use with standard cartridges. Antares Pharma has a portfolio of proprietary and partnered pro...

GVXXF : GoviEx Uranium (TSXV: GXU) Stock Analysis and Research Report

2017-10-30 - Tom

Vancouver-based GoviEx Uranium Inc. is a growing Africa-focused uranium company with a strong shareholder base, a robust project development pipeline, jurisdictional diversification, considerable exploration potential, and one of the largest resource bases among publicly listed peers, with combined National Instrument 43-101 Measured & Indicated resources of 131.7 Mlbs U308 plus Inferred resources of 76.9 Mlbs U308. Mineral Properties Madaouela Uranium Project (Niger) Located ~10 km south of Arlit, and Areva's mining subsidiaries of Cominak and Somair, in north central Niger Deposits hosted within sandstones of the Tim Mersoi Basin Approved Mad 1 Mine Permit (Jan 2016), and ESIA (July 2015) Infrastructure includes: road access, labor, ground water and available grid power Integrated Development Plan (PFS) updated August 2015 Probable mineral reserves are 60.54 Mlbs U3O8 Uranium Recovery forecast at 93.7% Cash Operating Cos...

ONVO : Organovo Holdings Stock Analysis and Research Report

2017-10-30 - Asif

Organovo Holdings, Inc. is an early commercial stage company focused on developing and commercializing functional three-dimensional (“3D”) human tissues. Using its proprietary technologies and expertise in bioprinting, Organovo Holdings is building functional 3D human tissues that mimic key aspects of native biology, and can be used in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or diseased tissues and organs. Organovo Holdings is utilizing its proprietary bioprinting platform to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. Organovo Holdings is leveraging its unique tissue models to improve the current industry standard cell-based and animal model testing approaches, and the company believe its foundational approach provides it with the opportunity to fill many critical gaps in commercially available preclinical human tissue models as well as in tissue trans...

HTGM : HTG Molecular Diagnostics Stock Analysis and Research Report

2017-10-30 - Asif

HTG Molecular is a commercial stage company that develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. Molecular profiling is the collection of information about multiple molecular targets, such as DNA and RNA, also called biomarkers, in a biological sample. Molecular profiling information has many important applications, from basic research to molecular diagnostics in personalized medicine. Its technology can be used throughout that range of applications, which is just one of its many benefits. Its focus is on clinical applications. Its primary customer segments include biopharmaceutical companies, academic research centers and molecular testing laboratories. Historically, molecular profiling has faced several technical challenges in clinical applications. These include (i) limited “multiplexing,” which means only a few biomarkers could be tested in a single sample; (ii) the need for vast amount...

INSM : Insmed Stock Analysis and Research Report

2017-10-30 - Asif

Insmed is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. Its lead product candidate is ARIKAYCE, or amikacin liposome inhalation suspension (ALIS) (formerly known as liposomal amikacin for inhalation, or LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC), a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is a novel oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), an enzyme responsible for activating neutrophil serine proteases, which are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis (non-CF) bronchiectasis. INS1009 is an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmon...

ACRX : AcelRx Pharmaceuticals Stock Analysis and Research Report

2017-10-30 - Asif

AcelRx Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. Its lead product candidate, DSUVIA™ (known as ARX-04 outside of the United States), and its product candidate, ZALVISO®, utilize sublingual sufentanil, delivered via a non-invasive route of sublingual administration. The company anticipate developing a distribution capability and commercial organization to market and sell DSUVIA in the United States by itself, and potentially, in certain European Economic Area, or EEA, countries with strategic partners. In geographies where the company decide not to commercialize itself, the company may seek to out-license commercialization rights. The company intend to seek regulatory approval for ZALVISO in the United States and, if successful, potentially promote ZALVISO either by itself or with strategic partners. AcelRx Pharmaceuticals has chosen sufentanil as the therapeutic in...

MEET : MeetMe Stock Analysis and Research Report

2017-10-30 - Asif

The Meet Group is a fast-growing portfolio of mobile apps that brings together people around the world for new connections. Its mission is to meet the universal need for human connection. The company operate location-based social networks for meeting new people on mobile platforms, including on iPhone, Android, iPad and other tablets, and on the web that facilitate interactions among users and encourage users to connect and chat with each other. Given consumer preferences to use more than a single mobile application, MeetMe is adopting a brand portfolio strategy, through which the company offer products that collectively appeal to the broadest spectrum of consumers. MeetMe is consolidating the fragmented mobile meeting sector through strategic acquisitions, leveraging economies and innovation to drive growth. On October 3, 2016 the company completed its acquisition of Skout, Inc. (“Skout”), and on April 3, 2017 the company completed its acquisition of Ifwe Inc. (“if(the company)”), b...

ROX : Castle Brands Stock Analysis and Research Report

2017-10-30 - Asif

The company develop and market premium and super premium brands in the following beverage alcohol categories: rum, whiskey, liqueurs, vodka and tequila. The company also develop and market related non-alcoholic beverage products, including Goslings Stormy Ginger Beer. The company distribute its products in all 50 U.S. states and the District of Columbia and in thirteen primary international markets, including Ireland, Great Britain, Northern Ireland, Germany, Canada, France, Finland, Norway, Sweden, Denmark, and the Duty Free markets. The company market the following brands, among others: Goslings rum® Goslings Stormy Ginger Beer Goslings Dark ‘n Stormy® ready-to-drink cocktail Jefferson’s® bourbon Jefferson’s Reserve® Jefferson’s Ocean Aged at Sea® Jefferson’s Wine Finish Collection Jefferson’s The Manhattan: Barrel Finished Cocktail Jefferson’s Chef’s Collaboration Jefferson’s Wood Experiment Jefferson’s Presidential Select™ Jefferson’s Straight...

CHK : Chesapeake Energy Corporation Stock Analysis and Research Report

2017-10-30 - Asif

The company own interests in approximately 22,700 oil and natural gas wells and produced an average of approximately 575 mboe per day in the 2016 fourth quarter, net to its interest. Chesapeake Energy has a large and geographically diverse resource base of onshore U.S. unconventional natural gas and liquids assets. Chesapeake Energy has leading positions in the liquids-rich resource plays of the Eagle Ford Shale in South Texas, the Utica Shale in Ohio, the Anadarko Basin in northwestern Oklahoma and the stacked pay in the Powder River Basin in Wyoming. Its natural gas resource plays are the Haynesville/Bossier Shales in northwestern Louisiana and East Texas and the Marcellus Shale in the northern Appalachian Basin in Pennsylvania. The company also own an oil and natural gas marketing business. The Company's estimated proved reserves as of December 31, 2016, were 1.708 bboe, an increase of 204 mmboe or 14%, from 1.504 bboe as of December 31, 2015. The increase in estimated proved res...

AVIR : Aviragen Therapeutics Stock Analysis and Research Report

2017-10-30 - Asif

Aviragen Therapeutics is focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three Phase 2 clinical stage compounds: BTA074, an antiviral treatment for condyloma caused by human papillomavirus types 6 & 11; vapendavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; and BTA585 (enzaplatovir), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections. The company also have a preclinical RSV non-fusion inhibitor program. In April 2017, the company engaged Stifel, Nicolaus and Company, Incorporated (“Stifel”) as its advisor to assist with the exploration of strategic alternatives (the “Strategic Review”). Stifel is providing a range of advisory services aimed to enhance stockholder value. The alternatives to be considered may include, but are not l...

UNXL : Uni-Pixel Stock Analysis and Research Report

2017-10-30 - Asif

Uni-Pixel, Inc. (NASDAQ: UNXL) develops and markets high performance metal mesh capacitive touch sensors to the touch screen and flexible displays markets. Its roll-to-roll electronics manufacturing process patterns fine line conductive elements on thin films. The company market its technologies for touch panel sensor and hard coat resin for cover glass replacement and protective cover film applications under the XTouch™ and Diamond Guard® brands. The company believe Uni-Pixel is one of the technology leaders in the optical design and manufacturing of large area microstructured polymer film materials and related technologies for the display, flexible electronics and automotive industries. Its microstructured polymer films, which the company refer to as Performance Engineered Films (PEFs), are designed to lower the cost and improve functionality and performance of devices in the markets they address. The company make transparent conductive films and flexible electronic films based o...

Australian Hedge Fund Incubators

2017-10-28 - Wilton

I've been doing some research on hedge fund incubators, and particularly Austrlian hedge fund incubators. Here is a list of the players I've found: Benelong Funds " Bennelong Funds Management acquires, incubates and distributes active funds from Australia and around the globe. We have a proud history of identifying and partnering with quality boutique asset managers, offering high-grade investment solutions. As equity partners in their individual businesses, each asset manager’s goals are aligned with those of their investors, providing greater impetus to achieve superior outcomes. While each boutique has its own distinctive philosophy and a dynamic and highly disciplined approach, they collectively believe in the benefits of active investment management. As such, they strive for out-performance, always seeking opportunities to maximise returns within their robust risk management frameworks. Globally, we have over AUD9 billion funds under...

XTNT : Xtant Medical Holdings Stock Analysis and Research Report

2017-10-26 - Asif

Xtant Medical Holdings, Inc. develops, manufactures and markets class-leading regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. Xtant believes the following competitive strengths will be key drivers of future growth of Xtant: Portfolio of Proprietary Technologies: Xtant has developed a comprehensive portfolio of products that address a broad array of spinal pathologies, anatomies and surgical approaches in the complex spine and minimally invasive surgery (“MIS”) markets. To protect company innovative technologies and techniques, Xtant maintains and continues to grow its intellectual property por...

PTN : Palatin Technologies Stock Analysis and Research Report

2017-10-26 - Asif

Palatin Technologie is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its lead product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (“HSDD”), which is a type of female sexual dysfunction (“FSD”), defined as low desire with associated distress. In addition, Palatin has drug candidates and development programs for cardiovascular diseases and inflammatory diseases. The following drug development programs are actively under development: Bremelanotide, an as-needed subcutaneous injectable product for the treatment of HSDD in premenopausal women. Bremelanotide is a synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulat...

BBRY : BlackBerry Ltd Stock Analysis and Research Report

2017-10-26 - Asif

BlackBerry is securing a connected world, delivering innovative solutions across the entire mobile ecosystem and beyond. The Company secures the world’s most sensitive data across all endpoints – from cars to smartphones – making the mobile-first enterprise vision a reality. Founded in 1984 and based in Waterloo, Ontario, the Company operates offices in North America, Europe, Middle East and Africa, Asia Pacific and Latin America. The Company’s common shares are listed on the NASDAQ Global Select Market (“NASDAQ”) (NASDAQ: BBRY) and the Toronto Stock Exchange (“TSX”) (TSX: BB), and its Debentures are listed on the TSX (TSX: BB.DB.U). The Mobile Communications Industry Improvements in wireless network infrastructure and the rapid proliferation of mobile devices and applications in recent years are transforming the way that enterprises and individuals communicate and collaborate. In the enterprise, the mobile platform is becoming the primary computing platform and users now ex...

MEIP : MEI Pharma Stock Analysis and Research Report

2017-10-26 - Asif

MEI Pharma business purpose is the development of drugs for the treatment of cancer. Its portfolio of clinical drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of adults with newly diagnosed AML who are unfit for intensive chemotherapy, and patients with high or very high-risk MDS. In August 2016, MEI entered into an exclusive worldwide license, development and commercialization agreement with Helsinn for Pracinostat in AML, MDS and other potential indications. Its clinical development portfolio also includes ME-401, an oral inhibitor of PI3K delta being developed for B-cell malignancies, and ME-344, a mitochondrial inhibitor that has shown evidence of clinical activity in refractory solid tumors. MEI own exclusive worldwide rights to ME-401 and ME-344. MEI Pharma has an accumulated deficit of $174.3 million as of June 30, 2017, and may incur substantial net losses in the future as MEI advance its ...

TEVA : Teva Pharmaceutical Industries Stock Analysis and Research Report

2017-10-24 - Asif

Teva Pharmaceutical Industries is global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic medicines and a focused portfolio of specialty medicines. The company operate worldwide, with a significant presence in the United States, Europe and many other markets around the world. Its key strengths include itsworld-leading generics expertise and portfolio, focused specialty portfolio, robust R&D capabilities, global infrastructure and scale and dedicated leadership and employees. Teva Pharmaceutical believe company is strategically positioned to benefit from market, economic and regulatory trends in global healthcare. These trends include aging populations, the increasing prevalence of chronic diseases, economic pressure on governments and private payors to provide affordable healthcare solutions, legislative and regulatory reforms, scientific and technological advances, increased patient awareness...

JOBS : 51job Stock Analysis and Research Report

2017-10-24 - Asif

The company commenced its business in 1998. In March 2000, The founders incorporated a new holding company, now called 51job, Inc., as an exempted limited liability company in the Cayman Islands under the Cayman Islands Companies Law. Subsequently, 51job, Inc. acquired 51net.com Inc., or 51net, a British Virgin Islands company, and other subsidiaries to become the holding company of its corporate group. 51job operate as a foreign-invested enterprise in China through its wholly owned subsidiaries, 51net, which is the registered owner of is www.51job.com domain name, 51net Beijing and 51net HR, which are both Cayman Islands companies, as well as its PRC subsidiaries and affiliated Chinese entities, the primary ones being: Qianjin Network Information Technology (Shanghai) Co., Ltd., or Tech JV, which is owned by 51net, Qian Cheng and Wuhan AdCo, and holds licenses which allow it to provide online advertising, human resource related and value-added telecommunications services; Be...

MACK : Merrimack Pharmaceuticals Stock Analysis and Research Report

2017-10-23 - Asif

Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Merrimack's mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers. All its product candidates, including three in clinical studies and several others in preclinical development, fit into its strategy of (1) understanding the biological problems the company is trying to solve, (2) designing specific solutions and (3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes. On April 3, 2017, Merrimack Pharmaceuticals announced that the company commenced operating as a refocused research and clinical development company in connection with the completion of Merrimack's previously announced transaction, or the asset sa...

ADMP : Adamis Pharmaceuticals Stock Analysis and Research Report

2017-10-23 - Asif

Adamis Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy. the company is currently developing several products in the allergy and respiratory markets, including its Epinephrine Injection pre-filled syringe, or PFS, product for use in the emergency treatment of acute allergic reactions, including anaphylaxis; albuterol (APC-2000) and fluticasone (APC-4000) Dry Powder Inhaler, or DPI, products for the treatment of bronchospasm and asthma, respectively; and a steroid hydrofluoroalkane, or HFA metered dose inhaler product (APC-1000) for the treatment of asthma. Adamis's goal is to create low cost therapeutic alternatives to existing treatments. Consistent across all specialty pharmaceuticals product lines, the company intend to submit Section 505(b)(2) New Drug Applications, or NDAs, or Section 505(j) Abbreviated New Drug Applications, or ANDAs, to the U.S. Food and Drug ...

BLRX : BioLineRx Ltd Stock Analysis and Research Report

2017-10-23 - Asif

BioLineRx is a clinical stage biopharmaceutical development company dedicated to identifying, in-licensing and developing therapeutic candidates that have advantages over currently available therapies or that address unmet medical needs. Its current development and commercialization pipeline consists of a clinical-stage therapeutic candidate − BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; a near-clinical candidate – AGI-134, a recently acquired immuno-oncology agent in near-clinical development for solid tumors; and a product that is being commercialized − BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution , which has been launched for sale in Europe as a medical device for the non-surgical removal of benign skin lesions. In addition, BioLineRx has five other therapeutic candidates in various stages of clinical and preclinical development. BioLineRx generate its pipeline by systematicall...

IDRA : Idera Pharmaceuticals Stock Analysis and Research Report

2017-10-23 - Asif

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. Idera Pharmaceuticals use two distinct proprietary drug discovery technology platforms to design and develop drug candidates: its Toll-like receptor, or TLR, targeting technology and its third-generation antisense, or 3GA, technology. Idera Pharmaceuticals developed these platforms based on its scientific expertise and pioneering work with synthetic oligonucleotides as therapeutic agents. Using its TLR targeting technology, Idera Pharmaceuticals design synthetic oligonucleotide-based drug candidates to modulate the activity of specific TLRs. In addition, using its 3GA technology, Idera Pharmaceuticals is developing drug candidates to turn off the messenger RNA, or mRNA, associated with disease causing genes. Idera Pharmaceuticals believe its 3GA technology may potentially reduce the immunoto...

IMNP : Immune Pharmaceuticals Stock Analysis and Research Report

2017-10-23 - Asif

Immune Pharmaceuticals Inc., together with its subsidiaries (collectively, “Immune” or the “Company”) is a clinical stage biopharmaceutical company specializing in the development of novel targeted therapeutic agents in the fields of immuno-inflammation, dermatology and immuno-oncology. The Company’s lead product candidate is bertilimumab, a clinical-stage, first-in-class, fully human antibody, which targets eotaxin-1, a key regulator of immuno-inflammation. The Company is developing bertilimumab for bullous pemphigoid (“BP”) an orphan auto-immune skin blistering disease, and ulcerative colitis (“UC”) a disease that causes inflammation and ulcers in the lining of the large intestine. Immune filed an orphan drug application with the Office of Orphan Products Development of the FDA to obtain Orphan Drug Designation for bertilimumab in BP on February 24, 2017. The Company’s asset portfolio includes NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of at...

ARLZ : Aralez Pharmaceuticals Stock Analysis and Research Report

2017-10-23 - Asif

Aralez is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients’ lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Its parent corporation, Aralez Pharmaceuticals Inc., was incorporated under the British Columbia Business Corporations Act (“BCBCA”) on December 2, 2015. its global headquarters is located in Mississauga, Ontario, Canada, its U.S. headquarters is located in Princeton, New Jersey, United States, and its Irish headquarters is located in Dublin, Ireland. Aralez was formed for the purpose of facilitating the business combination of POZEN Inc., a Delaware corporation (“Pozen”), and Tribute Pharmaceuticals Canada Inc., a corporation incorporated under the laws of the Province of Ontario, Canada (“Tribute”), which transaction closed on February 5, 2016. On February 5, 2016, pursuant to an Agreement and Plan of Merger and Arr...

NVCN : Neovasc Stock Analysis and Research Report

2017-10-23 - Asif

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease and the Neovasc Reducer for the treatment of refractory angina. In 2009, Neovasc started initial activities to develop novel technologies for catheter-based treatment of mitral valve disease. Based on the early positive results of these activities, the Company formally launched a program to develop the Tiara. Neovasc established a separate entity, NTI, in March 2013 to develop and own the intellectual property related to the Tiara (Neovasc has transferred all intellectual property related to Tiara to NTI). On February 3, 2014, Neovasc announced the first human implant of the Tiara under special access compassionate use exemptions. Subsequently sixteen additional patients have been implanted with the Tiara (twelve under compas...

AKS : AK Steel Holding Corporation Stock Analysis and Research Report

2017-10-23 - Asif

AK Steel Holding is the only steelmaker in North America that can produce all three major categories of flat-rolled steels—namely carbon, stainless and electrical. In addition, the company is the only domestic producer of flat-rolled steels that operates both blast furnaces and electric arc furnaces, providing it operational flexibility and the opportunity to innovate across markets and within its product portfolios. AK Steel operate eight steelmaking and finishing plants, two coke plants, a metallurgical coal production facility and two tube manufacturing plants across six states (Indiana, Kentucky, Michigan, Ohio, Pennsylvania and West Virginia) and a tube manufacturing plant in Mexico. These operations produce flat-rolled carbon steels, including premium-quality coated, cold-rolled and hot-rolled carbon steel products, and specialty stainless and electrical steels that the company sell in sheet and strip form, as well as carbon and stainless steel that the company manufacture into w...

EGLT : Egalet Corporation Stock Analysis and Research Report

2017-10-20 - Asif

Egalet Corporation is a fully integrated specialty pharmaceutical company developing, manufacturing and commercializing innovative treatments for pain and other conditions. Given the need for acute and chronic pain products and the issue of prescription abuse, the company focused on bringing non-narcotic and abuse-deterrent (“AD”) opioid formulations to patients and physicians. Egalet is currently marketing ARYMO® ER (morphine sulfate) extended-release (“ER”) tablets, for oral use CII (“ARYMO ER”), SPRIX® (ketorolac tromethamine) Nasal Spray (“SPRIX Nasal Spray”), and OXAYDO® (oxycodone HCI, USP) tablets for oral use only—CII (“OXAYDO”). ARYMO ER, an ER morphine product formulated with abuse-deterrent properties and approved for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, is its first product developed using its proprietary Guardian™ Technology. Egalet acquired, and...

PIRS : Pieris Pharmaceuticals Stock Analysis and Research Report

2017-10-20 - Asif

Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops Anticalin® protein-based drugs to target validated disease pathways in a unique and transformative way. Pieris' pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. Each of its development programs focus on the following: 300-Series oncology drug candidates are multispecific Anticalin®-based proteins designed to engage immunomodulatory targets and consist of a variety of multifunctional biotherapeutics that genetically link antibody with one or more Anticalin proteins, thereby constituting...

RGLS : Regulus Therapeutics Stock Analysis and Research Report

2017-10-20 - Asif

Regulus Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class drugs targeting micro RNAs to treat diseases with significant unmet medical need. Regulus was formed in 2007 when Alnylam Pharmaceuticals, Inc., or Alnylam, and Ionis Pharmaceuticals, Inc., or Ionis, contributed significant intellectual property, know-how and financial and human capital to pursue the development of drugs targeting micro RNAs pursuant to a license and collaboration agreement. Its most advanced program, under its strategic alliance with Sanofi, is RG-012, an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations, currently with no approved therapy available. micro RNAs are naturally occurring ribonucleic acid, or RNA, molecules that play a critical role in regulating key biological pathways. Scientific research has shown that an imbalance, or dysregulation, of micro RNAs is dire...

PSDV : pSivida Corporation Stock Analysis and Research Report

2017-10-20 - Asif

pSivida Corporation develop sustained-release drug delivery products that deliver drugs at a controlled and steady rate for months or years. pSivida hss developed three of the four sustained-release ophthalmic products currently approved by the U.S. FDA for treatment of back-of-the-eye diseases. Its product development programs are focused primarily on utilizing its core Durasert technology platform to deliver drugs to treat chronic diseases. Durasert three-year uveitis is its most advanced development-stage product, and is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis) for a period of three years. Durasert three-year uveitis met its primary efficacy endpoint of prevention of recurrence of uveitis through six months with a p value of < 0.001 in two ongoing pivotal Phase 3 clinical trials. pSivida anticipate filing an NDA with the FDA in late December 2017 or early January 2018. In July 2017, pSivida amended its co...

CNAT : Conatus Pharmaceuticals Stock Analysis and Research Report

2017-10-20 - Asif

Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. The company is developing emricasan, a first-in-class, orally active pan-caspase protease inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. Conatus believe that by reducing the activity of these enzymes, caspase inhibitors have the potential to interrupt the progression of a variety of diseases. Conatus plan to continue advancing toward initial registration of emricasan for patients with cirrhosis due to nonalcoholic steatohepatitis, or NASH, with parallel development toward registration of emricasan for patients with NASH fibrosis. itscurrent clinical program for emricasan includes the following randomized, double-blind, placebo-controlled Phase 2b clinical trials: *Phase 2b ENCORE-PH (Portal H...

TVIA : TerraVia Holdings Stock Analysis and Research Report

2017-10-20 - Asif

TerraVia is a food, nutrition and specialty ingredients company that harnesses the power of algae, the origin of all plants. Its innovative platform uses microalgae to produce high-value triglyceride oils, proteins, fibers, micronutrients and other ingredients. The inherent flexibility of its technology platform and the broad usage of these materials across multiple industries allow us to approach a wide range of customers across myriad end markets. TerraVia has streamlined its strategy to focus on food, nutrition and specialty ingredient products and began to more broadly commercialize these products in 2015, and in May 2016, TerraVia changed its name from “Solazyme, Inc.” to “TerraVia Holdings, Inc.”, and changed its Nasdaq ticker listing symbol from SZYM to TVIA. With the transition to the TerraVia brand and its refined focus on food, nutrition and specialty ingredients, TerraVia announced in March 2016 its intention to attract a new CEO with proven industry experience in food and n...

CRBP : Corbus Pharmaceuticals Holdings Stock Analysis and Research Report

2017-10-19 - Asif

Corbus Pharmaceuticals is a clinical stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases with clear unmet medical needs. Its product anabasum is a novel synthetic oral endocannabinoid-mimetic drug that is intended to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Anabasum is a synthetic, rationally-designed oral small molecule drug that selectively binds to the cannabinoid receptor type 2, or CB2, found on activated immune cells, fibroblasts and muscle cells. Anabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. These endogenous resolution pathways are normally activated in healthy individuals during the course of normal immune responses but are dysfunctional in chronic inflammatory and fibrotic disease...

OCLR : Oclaro Stock Analysis and Research Report

2017-10-19 - Asif

During its fiscal year 2017, Oclaro was one of the leading providers of optical components and modules for the long-haul, metro and data center markets. Leveraging more than three decades of laser technology innovation and photonics integration, Oclaro provide differentiated solutions for optical networks and high-speed interconnects driving the next wave of streaming video, cloud computing, application virtualization and other bandwidth-intensive and high-speed applications. Oclaro has research and development ("R&D") and chip fabrication facilities in China, Italy, Japan, United Kingdom and the United States. Oclaro also have contract manufacturing sites in Asia, with design, sales and service organizations in most of the major regions around the world. Oclaro's customers include ADVA Optical Networking; Amazon.com, Inc.; Ciena Corporation; Cisco Systems, Inc. ("Cisco"); Coriant GmbH ("Coriant"); Google Inc.; Huawei Technologies Co. Ltd ("Huawei"); Juniper Networks, Inc.; Nokia...

CTRV : Contravir Pharmaceuticals Stock Analysis and Research Report

2017-10-19 - Asif

Contravir Pharmaceuticals is a biopharmaceutical company focused on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. Contravir is developing two compounds to treat HBV infection, TXL and CRV431. TXL is a highly potent oral lipid prodrug of tenofovir. Prodrugs are designed to improve the characteristics of drugs, such as better efficacy, lower pill burden, improved safety, etc. Another prodrug of tenofovir, Viread®, is approved for the treatment of HIV and HBV infections. CRV431 is a novel drug candidate also designed for the treatment of HBV infection that the company acquired through its merger with Ciclofilin Pharmaceuticals Inc. CRV431 has been designed to target enzymes (“cyclophilins”) that play a key role in the HBV viral life cycle. Contravir is also developing an antiviral asset known as VALNIVUDINE, VALNIVUDINE is an orally available, small molecule compound being developed for the prevention of post-herpetic ne...

BLPH : Bellerophon Therapeutics Stock Analysis and Research Report

2017-10-19 - Asif

Bellerophon Therapeutics is a clinical-stage therapeutics company focused on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Bellerophon's focus is the continued development of its nitric oxide therapy for patients with pulmonary hypertension, or PH, using its proprietary delivery system, INOpulse, with pulmonary arterial hypertension, or PAH, representing the lead indication. Its INOpulse platform is based on its proprietary pulsatile nitric oxide delivery device. In February 2016, Bellerophon announced positive data from the final analysis of its Phase 2 long-term extension clinical trial of INOpulse for PAH, which was Part 2 of its Phase 2 clinical trial of INOpulse for PAH. The data indicates a sustainability of benefit to PAH patients who received INOpulse therapy at the 75 mcg/kg of ideal body weight/hour dose for an average of greater than 12 hours per day and we...

DRYS : DryShips Stock Analysis and Research Report

2017-10-19 - Asif

DryShips Inc., a corporation organized under the laws of the Republic of the Marshall Islands, was formed on September 9, 2004. its principal executive offices are located at 109 Kifisias Avenue and Sina Street, Marousi, GR 151 24 Greece. Business Development Developments related to Ocean Rig On October 29, 2014, DryShips completed the issuance of 20,833 of its common shares (250,000,000 common shares before the reverse stock splits) in a public offering amounting to net proceeds to it of $332.9 million. On June 8, 2015, Ocean Rig, successfully completed the offering of 28,571,428 shares of its common stock, par value $0.01 per share, at a price of $7.00 per share, resulting in proceeds of $194.1 million, after deducting placement fees. As a result of the offering DryShips lost itscontrolling financial interest in Ocean Rig, therefore, from June 8, 2015, Ocean Rig has been considered as an affiliated entity and not as a controlled subsidiary. On June 4, 2015, Dry...

BW : Babcock & Wilcox Enterprises Stock Analysis and Research Report

2017-10-19 - Asif

B&W is a leading technology-based provider of advanced fossil and renewable power generation and environmental equipment that includes a broad suite of boiler products, environmental systems, and services for power and industrial uses. B&W specialize in technology and engineering for power generation and various other industries, the related procurement, erection and specialty manufacturing of equipment, and the provision of related services, including: high-pressure equipment for energy conversion, such as boilers fueled by coal, oil, bitumen, natural gas, and renewables including municipal solid waste and biomass fuels; environmental control systems for both power generation and industrial applications to incinerate, filter, capture, recover and/or purify air, liquid and vapor-phase effluents from a variety of power generation and specialty manufacturing processes; aftermarket support for the global installed base of operating plants with a wide variety of products and tec...

OCUL : Ocular Therapeutix Stock Analysis and Research Report

2017-10-19 - Asif

Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its bioresorbable hydrogel-based drug product candidates are designed to provide extended delivery of therapeutic agents to the eye. Its lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are extended-delivery, drug-eluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose. Its intracanalicular inserts combine its hydrogel technology with U.S. Food and Drug Administration, or FDA, approved therapeutic agents with the goal of providing extended delivery of drug to the eye. Ocular also has...

VCEL : Vericel Corporation Stock Analysis and Research Report

2017-10-19 - Asif

Vericel Corporation is a leading developer of patient-specific expanded cell therapies for use in the treatment of patients with severe diseases and conditions. Vericel currently have three U.S. Food and Drug Administration (FDA) approved autologous cell therapy products in the United States. MACI ® (autologous cultured chondrocytes on porcine collagen membrane), is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults that was approved by the FDA on December 13, 2016. The first shipment and implantation of MACI occurred on January 31, 2017. Carticel® (autologous cultured chondrocytes) is an autologous chondrocyte implant indicated for the repair of symptomatic cartilage defects of the femoral condyle (medial, lateral or trochlea), caused by acute or repetitive trauma, in patients who have had an inadequate response to a prior arthroscopic or other s...

NTNX : Nutanix Stock Analysis and Research Report

2017-10-19 - Asif

Nutanix provide a leading next-generation enterprise cloud platform that converges traditional silos of server, virtualization and storage into one integrated solution that can also connect to public cloud services. Its software delivers the agility, scalability and pay-as-you-grow economics of the public cloud, while addressing enterprise requirements of application mobility, security, data integrity and control. Nutanix provide its customers with the flexibility to selectively utilize the public cloud for suitable workloads and specific use cases by enabling increasing levels of application mobility across private and public clouds. Nutanix has combined advanced web-scale technologies with elegant consumer-grade design to deliver a powerful enterprise cloud platform that elevates IT organizations by enabling them to focus on the applications and services that power their businesses. Nutanix's invisible infrastructure provides constant availability and low-touch management, enables a...

DXTR : Dextera Surgical Stock Analysis and Research Report

2017-10-16 - Asif

Dextera Surgical is commercializing and developing the MicroCutter 5/80TM stapler based on its proprietary ‘‘staple-on-a-strip’’ technology intended for use by thoracic, pediatric, bariatric, colorectal and general surgeons. Its proprietary ‘‘staple-on-a-strip’’ technology enables it to develop products with innovative features such as consistent staple forms, significantly reduced tool shaft diameter and increased articulation. Together these advances in stapler design enable surgeons to perform procedures on a broader array of patients and to develop procedural methods previously unattainable with existing products in the market. The MicroCutter 5/80, which is currently commercially available, is a cartridge-based stapler device with a 5 millimeter shaft diameter, 80 degrees of articulation, and a 30 millimeter staple line cleared for specified indications for use in the United States, and in the European Union, or EU, for a broader range of specified indications of use. Dextera esti...

PTX : Pernix Therapeutics Holdings Stock Analysis and Research Report

2017-10-16 - Asif

Pernix Therapeutics is a specialty pharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. Its strategy is to continue to create shareholder value by: growing sales of the existing products in its portfolio in various ways, including identifying new growth opportunities; and acquiring additional marketed specialty products or products close to regulatory approval to leverage its existing expertise and infrastructure. Pernix Therapeutics target underserved segments, such as central nervous system (CNS) indications, including neurology, pain and psychiatry. The company promote its core branded products to physicians through its sales forces. The company market its generic products through its wholly owned subsidiaries, Macoven and Cypress. Its branded products include Treximet, a medication indicated for the acute treatment of migraine attacks, with or without aura, ...

SNAP : Snapchat Stock Analysis and Research Report

2017-10-16 - Asif

Snap Inc. is a camera company. Snap believe that reinventing the camera represents Its greatest opportunity to improve the way that people live and communicate. Its products empower people to express themselves, live in the moment, learn about the world, and have fun together. Its flagship product, Snapchat, is a camera application that was created to help people communicate through short videos and images. The company call each of those short videos or images a Snap. On average, 173 million people use Snapchat daily, and over 3.0 billion Snaps are created every day. On average, its users visit Snapchat more than 20 times per day and spend over 30 minutes on Snapchat every day. Trends in User Metrics User Engagement The company define a Daily Active User as a registered Snapchat user who opens the Snapchat application at least once during a defined 24-hour period. The company measure average Daily Active Users for a particular quarter by calculating the averag...

OPK : Opko Health Stock Analysis and Research Report

2017-10-16 - Asif

Opko Health is a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Its diagnostics business includes BioReference Laboratories (“BioReference”), the nation’s third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform (in development). Opko Health's pharmaceutical business features Rayaldee , an FDA-approved treatment for secondary hyperparathyroidism (“SHPT”) in adults with stage 3 or 4 chronic kidney disease (“CKD”) and vitamin D insufficiency (launched in November 2016), and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO in November 2015 and pending approval for IV formulation), OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clini...

DVAX : Dynavax Technologies Stock Analysis and Research Report

2017-10-16 - Asif

Dynavax Technologies is a clinical-stage immunotherapy company focused on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor (“TLR”) stimulation. Dynavax current product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist that was selected for characteristics optimal for treatment of cancer, including high interferon induction. Directly injecting SD-101 into a tumor site optimizes its effect by ensuring proximity to tumor-specific antigens. In animal models, SD-101 demonstrated significant anti-tumor effects at both the injected site and at distant sites. Dynavax is conducting a clinical program intended to assess potential efficacy of SD-101 in a range of tumors and in combination with a range of treatments, including checkpoint inhibitors and...

BIOC : Biocept Stock Analysis and Research Report

2017-10-16 - Asif

Biocept is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or “liquid biopsy.” its current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic mutations that may qualify a subset of cancer patients for targeted therapy. Often, traditional methodologies such as tissue biopsies are insufficient or unavailable to provide the molecular subtype information necessary for clinical decisions. Biocept assays have the potential to provide more contemporaneous information on the characteristics of a patient’s disease compared with traditional methodologies such as tissue biopsy and radiographic imaging. Biocept current assays and planned future assays focus on key solid tumor indications utilizing its Target-Selectors liquid biopsy technology platform for the biomarker anal...

MNKD : MannKind Corporation Stock Analysis and Research Report

2017-10-16 - Asif

MannKind Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes. Its only approved product, Afrezza, is a rapid-acting inhaled insulin that was approved by the FDA on June 27, 2014 to improve glycemic control in adult patients with diabetes. Afrezza became available by prescription in United States retail pharmacies in February 2015. According to the Centers for Disease Control and Prevention, 30.3 million people in the United States had diabetes in 2015. Globally, the International Diabetes Federation has estimated that approximately 415.0 million people had diabetes in 2015 and approximately 642.0 million people will have diabetes by 2040. Afrezza is a rapid-acting inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler. Administered at the...

SYN : Synthetic Biologics Stock Analysis and Research Report

2017-10-16 - Asif

Synthetic Biologics is a late-stage clinical stage company focused on developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). the companyare also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis, and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). Product Pipeline: ![](https://www.sec.gov/Archives/edgar/d...

GERN : Geron Corporation Stock Analysis and Research Report

2017-10-16 - Asif

Geron Corporation is a biopharmaceutical company that currently supports the clinical stage development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies, by Janssen Biotech, Inc., or Janssen. Early clinical data, including molecular responses in essential thrombocythemia, or ET, and remission responses, including reversal of bone marrow fibrosis, in myelofibrosis, or MF, suggest imetelstat may have disease-modifying activity by inhibiting the progenitor cells of the malignant clones for the underlying diseases. In November 2014, Geron entered into a collaboration and license agreement, or the Collaboration Agreement, pursuant to which the company granted Janssen the exclusive rights to develop and commercialize imetelstat worldwide for all indications in oncology, including hematologic myeloid malignancies, and all other human therapeutic uses. The Collaboration Agreement became effective in December 2014 and the company received $35 million from Janssen ...

AFMD : Affimed N.V. Stock Analysis and Research Report

2017-10-15 - Asif

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called Natural Killer cells, or NK-cells, and T-cells. Its proprietary, next-generation bispecific antibodies, which it call TandAbs because of their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells. The company TandAbs have the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Due to their novel tetravalent architecture (which provides for four binding domains), its TandAbs bind to their targets with high affini...

AAPL : Apple Stock Analysis and Research Report

2017-10-15 - Asif

Apple, manufactures and markets mobile communication and media devices and personal computers, and sells a variety of related software, services, accessories, networking solutions and third-party digital content and applications. The Company’s products and services include iPhone®, iPad®, Mac®, Apple Watch®, Apple TV®, a portfolio of consumer and professional software applications, iOS, macOS®, watchOS® and tvOS™ operating systems, iCloud®, Apple Pay® and a variety of accessory, service and support offerings. The Company sells and delivers digital content and applications through the iTunes Store®, App Store®, Mac App Store, TV App Store, iBooks Store® and Apple Music® (collectively “Digital Content and Services”). The Company sells its products worldwide through its retail stores, online stores and direct sales force, as well as through third-party cellular network carriers, wholesalers, retailers and value-added resellers. In addition, the Company sells a variety of third-party Apple...

AMRS : Amyris Stock Analysis and Research Report

2017-10-15 - Asif

Amyris, Inc. is a leading industrial biotechnology company that is applying its technology platform to engineer, manufacture and sell high performance products into the Health and Nutrition, Personal Care and Performance Materials markets. Its proven technology platform allows it to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. Its biotechnology platform and industrial fermentation process replace existing complex and expensive chemical manufacturing processes. The Company has successfully used its technology to develop and produce at commercial volumes five distinct molecules. The company believe industrial synthetic biology represents a third industrial revolution, bringing together biology and engineering to generate new, more sustainable materials to meet the growing global demand for bio-based replacements for petroleum, and animal- or plant-derived ingredients. The company continue ...

WMIH : WMIH Corporation Stock Analysis and Research Report

2017-10-15 - Asif

WMIH Corp. (“WMIH”) is a corporation duly organized and existing under the laws of the State of Delaware. On May 11, 2015, WMIH merged with its parent corporation, WMI Holdings Corp., a Washington corporation (“WMIHC”), with WMIH as the surviving corporation in the merger (the “Merger”). The Merger occurred as part of the reincorporation of WMIHC from the State of Washington to the State of Delaware effective May 11, 2015 (the “Reincorporation Date”). WMIH, formerly known as WMIHC and Washington Mutual, Inc. (“WMI”), is the direct parent of WM Mortgage Reinsurance Company, Inc. (“WMMRC”) and WMI Investment Corp. (“WMIIC”) which has no assets or liabilities. Since emergence from bankruptcy on March 19, 2012 (the “Effective Date”), The company had limited operations other than WMMRC’s legacy reinsurance business, which is being operated in runoff mode. The company continue to operate WMMRC’s business in runoff mode and its primary strategic objective is to consummate one or more ac...

RAD : Rite Aid Corporation Stock Analysis and Research Report

2017-10-11 - Asif

Rite Aid is a pharmacy retail healthcare company, providing its customers and communities with a high level of care and service through various programs the company offer through its two reportable business segments, its Retail Pharmacy segment and its Pharmacy Services segment. The company accomplish its goal of delivering comprehensive care to its customers through its retail drugstores, RediClinic walk-in retail health clinics and transparent and traditional EnvisionRx and MedTrak PBMs. The company also offer fully integrated mail-order and specialty pharmacy services through EnvisionPharmacies. Additionally through EIC, EnvisionRx also serves one of the fastest-growing demographics in healthcare: seniors enrolled in Medicare Part D. When combined with its retail platform, this comprehensive suite of services allows it to provide value and choice to customers, patients and payors and allows it to succeed in today’s evolving healthcare marketplace. Rite Aid has two reportable bu...

NVDA : NVIDIA Corporation Stock Analysis and Research Report

2017-10-11 - Asif

Starting with a focus on PC graphics, NVIDIA invented the GPU to solve some of the most complex problems in computer science. The company has extended its emphasis in recent years to the revolutionary field of AI. NVIDIA delivers value to its customers through PC, mobile and cloud architectures. Vertical integration enables it to bring together hardware, system software, programmable algorithms, libraries, systems and services to create unique value for the markets it serve. The company specialize in markets in which GPU-based visual computing and accelerated computing platforms can provide enhanced throughput for applications. NVIDIA has two reportable segments - GPU and Tegra Processor - are based on a single underlying graphics architecture. From its proprietary processors, The company have created specialized platforms that target the four large markets where its expertise is critical: Gaming, Professional Visualization, Datacenter, and Automotive. NVIDIA's GPU product brands...

FIT : Fitbit Stock Research Analysis and Report

2017-10-11 - Asif

Fitbit's mission is to help people lead healthier, more active lives by empowering them with data, inspiration, and guidance to reach their goals. Fitbit is transforming the way millions of people around the world achieve their health and fitness goals. The Fitbit platform combines wearable devices with connected health solutions via software and services, including an online dashboard and mobile apps, data analytics, motivational and social tools, personalized insights, and virtual coaching through customized fitness plans and interactive workouts. Its platform helps people become more active, exercise more, sleep better, eat smarter, and manage their weight. Fitbit appeals to a large, mainstream health and fitness market by addressing these key needs with advanced technology embedded in simple-to-use products and services. The company pioneered the wearable device market starting in 2007, and since then, The company have grown into a leading global health and fitness brand. Fi...

TSLA : Tesla Motors Stock Analysis and Research Report

2017-10-09 - Asif

Tesla Motors's mission is to accelerate the world’s transition to sustainable energy. The company design, develop, manufacture, lease and sell high-performance fully electric vehicles, solar energy generation systems and energy storage products. The company also offer maintenance, installation, operation and other services related to its products. Automotive Tesla Motors production vehicle fleet includes Model S premium sedan and Model X sport utility vehicle, which are its highest-performance and most capable vehicles, and beginning in July 2017, its Model 3, a lower priced sedan designed for the mass market. The company continue to enhance its vehicle offerings with enhanced Autopilot options, Internet connectivity and free over-the-air software updates. The company continually deploy its internally developed software into the vehicle fleet, depending on the hardware of the vehicle, to provide additional safety and convenience features. The company are also actively working ...

IDXG : Interpace Diagnostics Group Stock Analysis and Research Report

2017-10-09 - Asif

Interpace Diagnostics Group is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services. The company develop and commercialize molecular diagnostic tests and related first line assays principally focused on early detection of patients at high risk of cancer and leverage the latest technology and personalized medicine for improved patient diagnosis and management. PancraGEN, ThyGenX, ThyraMIR, and BarreGEN The company currently has three commercialized molecular diagnostic assays in the marketplace for which the company is reimbursed by Medicare and multiple private payers: PancraGEN®, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its proprietary PathFinder platform; ThyGenX®, which assesses thyroid nodules for risk of malignancy; and ThyraMIR®, which assesses thyroid nodules for risk of malignancy utiliz...

XXII : 22nd Century Group Stock Analysis and Research Report

2017-10-09 - Asif

22nd Century Group is a plant biotechnology company focused on (i) potentially reduced risk tobacco cigarettes and smoking cessation products produced from modifying the nicotine content in tobacco plants through genetic engineering and plant breeding, and (ii) research and development of unique cannabis/hemp plants through genetic engineering and plant breeding to alter levels of cannabinoids for new medicines and improved agricultural uses. The company has an extensive intellectual property portfolio of issued patents and patent applications relating to the tobacco and cannabis plants. Its management team is focused on monetizing its intellectual property portfolio, obtaining regulatory approval to market both its reduced exposure cigarettes and its smoking cessation product in development, and developing and commercializing high value products derived from its unique cannabis/hemp plants. Additional information about its business and operations is contained in tis Annual Report on ...

NVAX : Novavax Stock Analysis and Research Report

2017-10-09 - Asif

Novavax is a clinical-stage biotechnology company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. Using innovative proprietary recombinant nanoparticle vaccine technology, The company produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Its vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical to disease pathogenesis. Its product pipeline targets a variety of infectious diseases, with clinical vaccine candidates for respiratory syncytial virus (“RSV”) and Ebola virus (“EBOV”), and preclinical programs for Zika virus (“ZIKV”), influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates. The company is also developing immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. Its lead adjuvant, Matrix...

BPMX : BioPharmX Corporation Stock Analysis and Research Report

2017-10-09 - Asif

BioPharmX is a specialty pharmaceutical company focused on utilizing its proprietary drug delivery technologies to develop and commercialize novel prescription and over‑the‑counter, or OTC, products that address large markets in dermatology and women’s health. The company's objective is to develop products that treat health or age‑related conditions that: (1) are not presently being addressed or treated or (2) are currently treated with drug therapies or drug delivery approaches that are sub‑optimal. The company's strategy is designed to bring new products to market by identifying optimal delivery mechanisms and/or alternative applications for United States Food and Drug Administration, or FDA, approved active pharmaceutical ingredients, or APIs, and biological materials, while, in appropriate circumstances, reducing the time, cost and risk typically associated with new product development by repurposing drugs with demonstrated safety profiles and, when applicable, taking advantage of ...

ARRY : Array BioPharma Stock Analysis and Research Report

2017-10-02 - Asif

Array is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule cancer therapies. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics). The company have received a total of $1.0 billion in research funding and in up-front and milestone payments from partners from inception through June 30, 2017 , including $292.0 million in initial payments from strategic agreements that The company entered into over the last ten years. The company received an up-front cash payment of $85.0 million upon the March 2015 effective date of the asset transfer agreement with Novartis for binimetinib, $30.0 million in January 2016 from Pierre Fab...

SPHS : Sophiris Bio Stock Analysis and Research Report

2017-10-02 - Asif

Sophiris Bio is a clinical-stage biopharmaceutical company focused on developing innovative products for the treatment of urological diseases. The company headquartered in San Diego, California and The company common shares currently trade on The NASDAQ Capital Market. The company is currently developing topsalysin (PRX302) as a treatment for clinically significant localized prostate cancer and as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia, or BPH, commonly referred to as an enlarged prostate. In 2004, The company licensed exclusive rights to topsalysin from UVIC Industry Partnerships Inc., or UVIC, and The Johns Hopkins University, or Johns Hopkins, for the treatment of prostate cancer and in 2009, The company licensed exclusive rights to topsalysin from UVIC and Johns Hopkins for the treatment of the symptoms of BPH. In April 2010, The company entered into an exclusive license agreement with Kissei Pharmaceuticals Co., Ltd., or Kissei, pursuant t...

AVXL : Anavex Life Sciences Stock Analysis and Research Report

2017-10-02 - Asif

Anavex Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEXTM 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome. In November 2016, a Phase 2a clinical trial going over 52 weeks was completed for ANAVEXTM 2-73 in mild-to-moderate Alzheimer’s patients. This open-label randomized trial met both primary and secondary endpoints, and was designed to assess the safety and exploratory efficacy of ANAVEXTM 2-73 in 32 patients. ANAVEXTM 2-73 targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress ...

AVEO : AVEO Pharmaceuticals Stock Analysis and Research Report

2017-10-02 - Asif

AVEO Pharmaceuticals is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company proprietary platform has delivered unique insights into cancer and related diseases. The company's strategy is to leverage these biomarker insights and partner resources to advance the development of its clinical pipeline. The company is focused on developing its lead candidate tivozanib in North America as a treatment for renal cell carcinoma, or RCC. In addition, The company has entered into partnerships to fund the further development and commercialization of its clinical stage assets, including AV-380, ficlatuzumab, AV-203, and tivozanib for oncology indications outside of North America. The company is currently seeking a partner to develop the AV-353 platform, a preclinical asset, worldwide for the potential treatment of pulmonary arterial hypertension, or PAH. Going Concern AVEO Pharmaceutic...

PLX : Protalix BioTherapeutics Stock Analysis and Research Report

2017-10-02 - Asif

Protalix BioTherapeutics is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx® protein expression system, or ProCellEx. The company developed its first commercial drug product, ElelysoTM, using its ProCellEx system and The company is now focused on utilizing the system to develop a pipeline of proprietary, clinically superior versions of recombinant therapeutic proteins that primarily target large, established pharmaceutical markets and that in most cases rely upon known biological mechanisms of action. With its experience to date, The company believe ProCellEx will enable it to develop additional proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. The company is now also applying the unique properties of its ProCellEx system for the oral delivery of therapeutic proteins. On May 1, 2012, the F...

AAOI : Applied Optoelectronics Stock Analysis and Research Report

2017-10-02 - Asif

Applied Optoelectronics is a leading, vertically integrated provider of fiber-optic networking products, primarily for four networking end-markets: internet data center, cable television, or CATV, fiber-to-the-home, or FTTH, and telecommunication, or telecom. The company design and manufacture a range of optical communications products at varying levels of integration, from components, subassemblies and modules to complete turn-key equipment. In designing products for its customers, Applied Optoelectronics begins with the fundamental building blocks of lasers and laser components. From these foundational products, the company design and manufacture a wide range of products to meet its customers’ needs and specifications, and such products differ from each other by their end market, intended use and level of integration. The company primarily focused on the higher-performance segments within all four of its target markets, which increasingly demand faster connectivity and innovat...

MU: Micron Technology Stock Analysis and Research Report

2017-10-02 - Asif

Micron Technology is a world leader in innovative memory solutions. Through the company global brands – Micron ® , Crucial ® , Lexar ® , and Ballistix ® – the company broad portfolio of high-performance memory technologies, including DRAM, NAND, NOR Flash, and 3D XPoint™ memory, is transforming how the world uses information. Backed by more than 35 years of technology leadership, the company memory solutions enable the world's most innovative computing, consumer, enterprise storage, data center, mobile, embedded, and automotive applications. The accompanying consolidated financial statements include the accounts of Micron and the company consolidated subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America consistent in all material respects with those applied in the company Annual Report on Form 10-K for the year ended September 1, 2016. In the opinion of the company management, the accompanying unaudited consolida...

SGYP: Synergy Pharmaceuticals Stock Analysis and Research Report

2017-09-29 - Asif

Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. The company has pioneered discovery, research and development efforts around analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. The company discovered, are developing and control 100% worldwide rights to its proprietary uroguanylin based GI platform, which includes one commercial product, TRULANCE (plecanatide), and a second product candidate, dolcanatide. TRULANCE (plecanatide) Its first and only commercial product, TRULANCE™, is approved and marketed in the United States (U.S.), under the trademark name TRULANCE™, as a once-daily treatment for adults with chronic idiopathic constipation, or CIC. In clinical trials, TRULANCE helped improve stool consistency and provide more regular bowel movements. TRULANCE is the only prescription medication for CIC that c...

VRX: Valeant Pharmaceuticals International Stock Analysis and Research Report

2017-09-28 - Asif

Valeant Pharmaceuticals International, Inc. is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. We are diverse not only in our sources of revenue from our broad drug and medical device portfolio, but also among the therapeutic classes and geographies we serve. We generated revenues of $4,342 million and $4,792 million for the six months ended June 30, 2017 and 2016, respectively. Our portfolio of products falls into three reportable segments: (i) Bausch + Lomb/International, (ii) Branded Rx and (iii) U.S. Diversified Products. The Bausch + Lomb/International segment consists of: (i) sales in the U.S. of pharmaceutical products, OTC products a...

AUPH: Aurinia Pharmaceuticals Stock Analysis and Research Report

2017-09-28 - Asif

Aurinia is a clinical stage biopharmaceutical company with its head office located at #1203-4464 Markham Street, Victoria, British Columbia V8Z 7X8 where clinical, regulatory and business development functions of the Company are conducted. Aurinia has its registered office located at #201, 17904-105 Avenue, Edmonton, Alberta T5S 2H5 where the finance function is performed. The office of the CEO is located in Bellevue, Washington. Aurinia is organized under the Business Corporations Act (Alberta). Aurinia’s By-Law No. 2 was amended at a shareholder’s meeting held on August 15, 2013 to include provisions requiring advance notice for any nominations of directors by shareholders. Aurinia’s Common Shares are currently listed and traded on the NASDAQ under the symbol “AUPH” and on the TSX under the symbol “AUP”. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular LN. Aurinia has the following wholly-owned subsidiaries: ...

AMD: Advanced Micro Devices Stock Analysis and Research Report

2017-09-28 - Asif

We are a global semiconductor company with facilities around the world. Within the global semiconductor industry, we offer primarily: x86 microprocessors, as standalone devices or as incorporated as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs) and professional graphics processors; and server and embedded processors, semi-custom System-on-Chip (SoC) products and technology for game consoles. We also license portions of our intellectual property portfolio. In this section, we will describe the general financial condition and the results of operations of Advanced Micro Devices, Inc. and its wholly-owned subsidiaries (collectively, “us,” “our” or “AMD”), including a discussion of our results of operations for the quarter and six months ended July 1, 2017 compared to the quarter and six months ended June 25, 2016 , an analysis of changes in our financial condition and a discussion of our contractual obligations. We believe our fin...

NAK: Northern Dynasty Minerals Ltd Stock Analysis and Research Report

2017-09-27 - Asif

We are a mineral exploration company existing under the Business Corporations Act (British Columbia) focused on developing, through our subsidiaries, the Pebble copper-gold-molybdenum-silver mineral project located in the state of Alaska, U.S. (the Pebble Project). The Pebble Project is located in southwest Alaska, 19 miles (30 kilometers) from the village of Iliamna, and approximately 200 miles (320 kilometers) southwest of the city of Anchorage. Our Alaska mineral resource exploration business is operated through an Alaskan registered limited partnership, the Pebble Limited Partnership (the Pebble Partnership), in which we own a 100% interest through an Alaskan general partnership, the Northern Dynasty Partnership. Pebble Mines Corp., a 100% indirectly owned Alaskan subsidiary of the Company, is the general partner of the Pebble Partnership and responsible for its day-to-day operations. In February 2014, the EPA announced the initiation of a regulatory action under the CWA to c...

CYTR: CytRx Corporation Stock Analysis and Research Report

2017-09-27 - Asif

CytRx Corporation is a biopharmaceutical company specializing in oncology. Its focus is on the discovery, research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. Aldoxorubicin, it slead clinical candidate, has been tested in over 600 patients with various types of cancer. CytRx's lead product candidate is aldoxorubicin, a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is believed to concentrate the drug at the site of the tumor. Specifically, it is comprised of (6-maleimidocaproyl) hydrazine, an acid-sensitive molecule that is conjugated to doxorubicin. Its lead indication for aldoxorubicin is for patients with advanced soft tissue sarcomas (STS). It met with the FDA in March 2017 to discuss a regulatory pathway for a New Drug Application (NDA) for aldoxorubicin in STS. Aldoxorubicin has...

DCTH: Delcath Systems Company Stock Analysis and Research Report

2017-09-26 - Wilton

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) —is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, our system is in commercial development under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT®), where it has been used at major medical centers to treat a wide range of cancers of the liver. Our primary research focus is on ocular melanoma liver metastases (mOM) and intrahepatic cholangiocarcinoma (ICC), a type of primary liver cancer, and certain other cancers that are metastatic to the liver. We believe the disease states we are investigating represent a multi-billion dollar global market opportunity and a clear unmet medical need. Our clinical development p...

Five Ways You Can Help Make Fintel Better

2017-09-25 - Wilton

If you really like Fintel and you want to help out, this blog post is for you. Here are five simple things you can do that will help keep Fintel operating and growing. 1. Be a Friend, Support our Advertisers Every month we get a bill from Amazon, and as Fintel grows, so does that bill. In order to keep Fintel free, we allow advertisers to promote their products on our site. We get paid when you click an ad. They get paid when you purchase or subscribe to their products. We try to keep the advertising on Fintel as lightweight as possible, while maintaining enough revenue to keep the servers on (and cold). Fintel is not venture funded. It has been built from our own pockets. Support Fintel by supporting our advertisers. 2. Spread the Word If you really love Fintel, then you're the best person in the world to tell others about us. Besides clicking ads, this truly is the best gift you can provide. There are dozens of online stock communities that would love to have your parti...

Making Sense of the Ownership Filings - the 13D, 13G, and 13F

2017-08-24 - Wilton

Anybody who has browsed around Fintel has probably noticed that we track a lot of ownership data. The Securities and Exchange commission (the SEc) requires many funds and institutions to disclose their positions under certain circumstances, and this information can be very helpul when trying to guage investor sentiment in a company. This guide will walk you through the various forms and show how you can use Fintel to make more informed investing decisions. The 13D and 13G forms are "beneficial ownership" forms. The primary purpose of these forms is to understand control of a company. To that end, the 13D and G forms do not just disclose the shares directly held by an investor, but also shares indirectly held (but controlled) by that institution. These indirect shares include all the shares held by the clients of financial advisors. Another requirement of the beneficial ownership forms is that they include related parties to the funds. For example, the firm called "Point72"...